

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrAdvagraf[®]
tacrolimus extended-release capsules
0.5 mg, 1 mg, 3 mg and 5 mg capsules, for oral use
Immunosuppressant

Astellas Pharma Canada, Inc.
Markham, ON
L3R 0B8

Date of Initial Authorization:
August 10, 2009

Date of Revision:
SEP 23, 2024

Prograf[®] and Advagraf[®] are registered trademarks of Astellas
Pharma Inc. All other trademarks or registered trademarks
are the property of their respective owners.

Submission Control Number: 286250

414017-ADV-CAN

RECENT MAJOR LABEL CHANGES

7 WARNINGS AND PRECAUTIONS, Hematologic	12/2022
7 WARNINGS AND PRECAUTIONS, Renal	12/2022

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	6
4.3 Reconstitution	8
4.4 Administration	8
4.5 Missed Dose	8
5 OVERDOSAGE	8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	9
7 WARNINGS AND PRECAUTIONS	10
7.1 Special Populations	17
7.1.1 Pregnant Women	17
7.1.2 Breast-feeding	17
7.1.3 Pediatrics	17
7.1.4 Geriatrics	17
8 ADVERSE REACTIONS	18
8.1 Adverse Reaction Overview	18

8.2	Clinical Trial Adverse Reactions	18
8.3	Less Common Clinical Trial Adverse Reactions	22
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	24
8.5	Post-Market Adverse Reactions	24
9	DRUG INTERACTIONS	26
9.2	Drug Interactions Overview	26
9.3	Drug-Behavioural Interactions.....	26
9.4	Drug-Drug Interactions	26
9.5	Drug-Food Interactions.....	35
9.6	Drug-Herb Interactions.....	35
9.7	Drug-Laboratory Test Interactions.....	35
10	CLINICAL PHARMACOLOGY	35
10.1	Mechanism of Action.....	35
10.2	Pharmacodynamics	36
10.3	Pharmacokinetics	36
11	STORAGE, STABILITY AND DISPOSAL	45
12	SPECIAL HANDLING INSTRUCTIONS	45
PART II: SCIENTIFIC INFORMATION		46
13	PHARMACEUTICAL INFORMATION	46
14	CLINICAL TRIALS	47
14.1	Trial Design and Study Demographics	47
14.2	Study Results	51
15	MICROBIOLOGY	56
16	NON-CLINICAL TOXICOLOGY	56
PATIENT MEDICATION INFORMATION.....		62

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

De novo

Advagraf® (tacrolimus extended-release capsules) is indicated for prophylaxis of organ rejection in adult patients receiving allogeneic kidney and liver transplants.

Advagraf is to be used concomitantly with adrenal corticosteroids and mycophenolate mofetil (MMF) in *de novo* renal transplant recipients and adrenal corticosteroids in *de novo* liver transplants. Antibody induction therapy should also be used in kidney transplant recipients.

Conversion

Stable renal transplant patients may be converted from Prograf® (twice daily) to Advagraf (once daily), in combination with adrenal corticosteroids and MMF, based on equivalent tacrolimus whole blood trough concentrations. Stable liver transplant patients may be converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation), in combination with adrenal corticosteroids, based on equivalent tacrolimus whole blood trough concentrations (See 4 Dosage and Administration).

Any changes in immunosuppressive therapy must be initiated by physicians experienced in immunosuppressive therapy and the management of transplant patients.

1.1 Pediatrics

A safe and effective dose of Advagraf (extended-release formulation) in pediatric liver and kidney transplant recipients has not been determined.

1.2 Geriatrics

Experience with Advagraf in patients older than 65 years of age is limited.

2 CONTRAINDICATIONS

Advagraf (tacrolimus extended-release capsules) is contraindicated in patients with hypersensitivity to tacrolimus or to any ingredient in the formulation or component of the capsules. For a complete listing, see **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

- Increased susceptibility to infection and the possible development of lymphoma and skin cancer may result from immunosuppression (see **7 WARNINGS AND PRECAUTIONS, Carcinogenesis and Mutagenesis, and Immune**).
- Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe Advagraf (tacrolimus extended-release capsules). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient and should be consulted if a patient is converted to an alternative formulation so that therapeutic drug monitoring can be instituted.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Advagraf is a once-a-day oral formulation of tacrolimus. Advagraf therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.

Medication errors, including inadvertent, unintentional or unsupervised substitution of Prograf (immediate-release) or Advagraf (extended-release) tacrolimus formulations, have been observed. This has led to serious adverse events, including graft rejection, or other side effects which could be a consequence of either under- or over-exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist.

Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.

Patients converting from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) should be administered a single daily morning dose of Advagraf equivalent to the patient's previous stable total daily dose of Prograf (immediate-release formulation). Subsequent doses of Advagraf should be adjusted in order to maintain trough concentrations similar to those prior to conversion.

Due to intersubject variability following dosing with tacrolimus, individualization of the dosing regimen is necessary for optimal therapy.

Advagraf is to be used concomitantly with adrenal corticosteroids and mycophenolate mofetil (MMF) in *de novo* renal transplant recipients. Antibody induction therapy should be used in kidney transplant recipients. Advagraf is to be used concomitantly with adrenal corticosteroids in *de novo* liver transplants.

4.2 Recommended Dose and Dosage Adjustment

Initial dosage and typical tacrolimus whole blood trough concentrations are shown in Table 1 below; blood concentration details are described under **7 Warnings and Precautions – Monitoring and Laboratory Tests - Blood Concentration Monitoring**.

Table 1: Advagraf (tacrolimus extended-release capsules) – Summary of Initial Oral Dosage Recommendations and Typical Whole Blood Trough Concentrations

Patient Population	Recommended Initial Once Daily (AM) Oral Dose	Typical Whole Blood Trough Concentrations
Adult Kidney Transplant Patients	0.15-0.20 mg/kg/day	Month 1-3: 7-16 ng/mL Month 4-12: 5-15 ng/mL
Adult liver transplant	0.10-0.20 mg/kg/day	Day 1 to 60: 5 to 20 ng/mL Month 3 to 12: 5 to 15 ng/mL

The recommended starting oral dose of Advagraf for kidney transplant patients is 0.15 to 0.20 mg/kg and for liver transplant patients 0.10-0.20 mg/kg administered once daily in the morning. The initial dose of Advagraf should be administered within 24 hours of kidney transplantation and within 12-18 hours of liver transplantation. Dosing should be titrated to maintain the whole blood trough concentration levels noted above; blood concentration details are described under **7 Warnings and Precautions – Monitoring and Laboratory Tests - Blood Concentration Monitoring**.

Conversion from Prograf (immediate-release formulation) to Advagraf (extended-release formulation)

Stable kidney and liver transplant recipients can be converted from Prograf (immediate-release formulation) twice daily to once-daily Advagraf (extended-release formulations). Patients converting from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) should be administered a single daily morning dose of Advagraf (extended-release formulation) equivalent to the patient's previous stable total daily dose of Prograf (immediate-release formulation). The same target trough range and whole blood trough concentration monitoring should be used as with Prograf (immediate-release formulation) in order to maintain whole blood trough concentrations of tacrolimus similar to those prior to conversion.

In patients unable to take oral Advagraf (extended-release) capsules, therapy may be initiated with Prograf injection and the patient subsequently converted to oral Advagraf. The recommended starting dose of Prograf injection is 0.03-0.05 mg/kg/day (kidney) as a continuous IV infusion. Adult patients should receive doses at the lower end of the dosing range.

In a liver conversion adult study from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) (n=62), Advagraf dose adjustments were needed in approximately 16% of patients in the early conversion period. After conversion, it is strongly recommended that the tacrolimus blood trough be monitored every 4-7 days until stable within the desired therapeutic range.

Patients with Hepatic or Renal Dysfunction

Advagraf (extended-release formulation) has not been studied in patients with hepatic or renal dysfunction; the following are based on experiences obtained from use of Prograf (immediate-release formulation).

Due to the reduced clearance and prolonged half-life, patients with severe hepatic impairment (Pugh \geq 10) may require lower doses of Advagraf. Close monitoring of blood concentrations is warranted. Due to the potential for nephrotoxicity in patients with renal or hepatic impairment, these patients should receive doses at the lowest value of the recommended oral dosing range. Further reductions in dose below these ranges may be required.

Conversion from Cyclosporine to Advagraf

Tacrolimus should not be used simultaneously with cyclosporine. Patients converted from cyclosporine to Advagraf should receive the first Advagraf dose no sooner than 24 hours after the last cyclosporine dose. Dosing may be further delayed in the presence of elevated cyclosporine levels.

Conversion from Advagraf to Cyclosporine

Patients converted from Advagraf to cyclosporine should receive the first cyclosporine dose no sooner than 24 hours after the last Advagraf dose. Dosing may be further delayed in the presence of elevated tacrolimus levels.

Race

The data from Advagraf administration in *de novo* kidney transplant patients indicate that Black patients required a higher dose to attain comparable trough concentrations compared to White patients (Table 2).

Table 2: Advagraf (tacrolimus extended-release capsules) trough concentrations in kidney transplant patients

Time After Transplant	White n=160		Black n=41	
	Dose (mg/kg)	Mean Trough Concentration (ng/mL)	Dose (mg/kg)	Mean Trough Concentration (ng/mL)
Day 7	0.14	10.79	0.14	7.85
Month 1	0.14	11.11	0.18	10.83
Month 6	0.10	7.96	0.13	8.50
Month 12	0.09	7.54	0.12	7.52

4.3 Reconstitution

Not Applicable

4.4 Administration

Advagraf can be administered with or without food; however, doses should be administered in a consistent manner (see 10 Clinical Pharmacology).

4.5 Missed Dose

If a dose of Advagraf is missed, the dose may be taken up to 14 hours after the scheduled time without risk of overexposure (i.e., for a missed 8:00 am dose, take by 10:00 pm). Beyond the 14-hour time frame, the patient should wait until the usual scheduled time the following morning to take the next regular daily dose.

5 OVERDOSAGE

For management of a suspected drug overdose, contact your regional poison control centre.

Limited overdose experience with tacrolimus is available.

An overdose of 5 times the intended dose has been reported with Advagraf, followed by an adverse event of hypomagnesaemia that was successfully treated with medication.

Acute overdoses of up to 30 times the intended dose have been reported with Prograf (immediate-release formulation). Almost all cases have been asymptomatic and all patients recovered with no sequelae. Occasionally, acute overdose has been followed by adverse reactions consistent with those listed in the adverse reactions section except in one case where

transient urticaria and lethargy were observed. Based on the poor aqueous solubility and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus is not dialyzable to any significant extent; there is no experience with charcoal hemoperfusion. The oral use of activated charcoal has been reported in treating acute overdoses, but experience has not been sufficient to warrant recommending its use. General supportive measures and treatment of specific symptoms should be followed in all cases of overdose.


6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 3: Dosage Forms, Strengths, Composition and Packaging


Route of Administration	Dosage Form/Strength/Composition	Non-medicinal Ingredients
Oral	Capsules 0.5 mg, 1 mg, 3 mg and 5 mg	ethylcellulose, ferric oxide, gelatin, hypromellose, lactose, magnesium stearate, sodium lauryl sulfate and titanium dioxide

Advagraf is available for oral administration as hard gelatin capsules (tacrolimus extended-release capsules) containing the equivalent of 0.5 mg, 1 mg, 3 mg or 5 mg of anhydrous tacrolimus. Inactive ingredients include ethylcellulose, hypromellose, magnesium stearate and lactose. The ingredients are directly proportional across all capsule strengths. The capsule shells contain gelatin, titanium dioxide, sodium lauryl sulfate and ferric oxide.


Advagraf Capsules (tacrolimus extended-release capsules) 0.5 mg

Oblong capsules with a light yellow cap and an orange body. Capsules, supplied in 50-count blister packs (10 capsules per card), are imprinted with red “647” on the capsule body and “0.5 mg” on the capsule cap.


Advagraf Capsules (tacrolimus extended-release capsules) 1 mg

Oblong capsules with a white cap and an orange body. Capsules, supplied in 50-count blister packs (10 capsules per card), are imprinted with red “677” on the capsule body and “1 mg” on the capsule cap.

Advagraf Capsules (tacrolimus extended-release capsules) 3 mg

Oblong capsules with an orange cap and an orange body. Capsules supplied in 50-count blister packs (10 capsules per card), are imprinted with red “637” on the capsule body and “3 mg” on the capsule cap.

Advagraf Capsules (tacrolimus extended-release capsules) 5 mg

Oblong capsules with a grayish-red cap and orange body. Capsules, supplied in 50-count blister packs (10 capsules per card), are imprinted with red “687” on the capsule body and “5 mg” on the capsule cap.

on the capsule cap.

7 WARNINGS AND PRECAUTIONS

Please see the Serious Warnings and Precautions Box at the beginning of Part I: Health Professional Information.

General

Switching of Prograf (immediate-release formulation) or Advagraf (extended-release formulation) should be done under supervision of a transplant specialist. Inadvertent, unintentional or unsupervised switching of Prograf or Advagraf formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see 6 Dosage and Administration).

Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.

In *de novo* kidney and liver transplant patients, AUC₀₋₂₄ of tacrolimus for Advagraf (extended-release formulation) on day 1 is significantly lower in comparison with that for Prograf (immediate-release formulation) at equivalent doses. By day 4, tacrolimus exposure as measured by trough levels is similar for both formulations. All patients in the clinical kidney *de novo* studies received antibody induction therapy. All patients in the clinical liver *de novo* studies received adrenal corticosteroids with Advagraf. Advagraf is approved to be used in combination with adrenal corticosteroids and MMF in *de novo* kidney patients and approved to be used with adrenal corticosteroids in *de novo* liver patients.

In clinical studies for stable patients converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) on 1:1 (mg:mg) total daily dose basis, up to one-third of patients required dose adjustment after conversion during the early conversion period due to dosing errors, adverse events, or whole blood trough levels outside the target range. Tacrolimus whole blood trough levels should be measured and closely monitored prior to and after conversion. Conversion to Advagraf (extended-release formulation) has primarily been studied from Prograf (immediate-release formulation) in combination with adrenal corticosteroids and MMF based on equivalent tacrolimus whole blood trough concentrations.

Tacrolimus is extensively metabolized by the mixed-function oxidase system, primarily the cytochrome P450 system (CYP3A). Since tacrolimus is metabolized mainly by CYP3A enzyme systems, substances known to inhibit these enzymes may decrease the metabolism or increase

bioavailability of tacrolimus with resultant increases in whole blood or plasma levels. Drugs known to induce these enzyme systems may result in an increased metabolism of tacrolimus or decreased bioavailability as indicated by decreased whole blood or plasma levels. Monitoring of blood levels and appropriate dosage adjustments in transplant patients are essential when such drugs are used concomitantly (see **4 DOSAGE AND ADMINISTRATION, Recommended Dose and Dose Adjustment**, and **9 DRUG INTERACTIONS**).

Advagraf contains lactose and is not recommended for patients with rare hereditary disease of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Carcinogenesis and Mutagenesis

An increased incidence of malignancy is a recognized complication of immunosuppression in recipients of organ transplants. The most common forms of neoplasms are non-Hodgkin's lymphomas and carcinomas of the skin. As with other immunosuppressive therapies, the risk of developing lymphomas and other malignancies, particularly of the skin, may be higher in Advagraf recipients than in the normal, healthy population. This risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.

Lymphoproliferative disorders associated with Epstein-Barr Virus infection have been seen with tacrolimus. It has been reported that reduction or discontinuation of immunosuppression may cause the lesions to regress.

No evidence of genotoxicity was seen in bacterial (*Salmonella* and *E. coli*) or mammalian (Chinese hamster lung-derived cells) *in vitro* assays of mutagenicity, the *in vitro* CHO/HGPRT assay of mutagenicity, or *in vivo* clastogenicity assays performed in mice; tacrolimus did not cause unscheduled DNA synthesis in rodent hepatocytes.

Carcinogenicity studies were carried out in male and female rats and mice. In the 80-week mouse study and in the 104-week rat study, no relationship of tumor incidence to tacrolimus dosage was found. The highest doses used in the mouse and rat studies were 0.8 - 2.5 times (mice) and 3.5 - 7.1 times (rats) the recommended clinical dose range when corrected for body surface area.

Cardiovascular

Hypertension is a common adverse effect of tacrolimus therapy (see 8 Adverse Reactions). Mild or moderate hypertension is more frequently reported than severe hypertension. Antihypertensive therapy may be required; the control of blood pressure can be accomplished with any of the common antihypertensive agents. Since tacrolimus may cause hyperkalemia, potassium-sparing diuretics should be avoided. Tacrolimus should be discontinued in patients in whom hypertension and hyperkalemia cannot be controlled.

While calcium-channel blocking agents can be effective in treating tacrolimus-associated hypertension, care should be taken since interference with tacrolimus metabolism may require a dosage reduction (see 9 Drug Interactions).

Heart failure, myocardial hypertrophy and arrhythmia have been reported in association with the administration of Prograf (immediate-release formulation). Myocardial hypertrophy has been reported in association with the administration of tacrolimus as Prograf (immediate-release formulation), and is generally manifested by echocardiographically demonstrated concentric increases in left ventricular posterior wall and interventricular septum thickness. Hypertrophy has been observed in infants, children and adults. This condition appears reversible in most cases following dose reduction or discontinuance of therapy. In a group of 20 patients with pre- and post-treatment echocardiograms who showed evidence of myocardial hypertrophy, mean tacrolimus whole blood concentrations during the period prior to diagnosis of myocardial hypertrophy ranged from 11 to 53 ng/mL in infants (n=10, age 0.4 to 2 years), 4 to 46 ng/mL in children (n=7, age 2 to 15 years) and 11 to 24 ng/mL in adults (n=3, age 37 to 53 years).

In patients who develop renal failure or clinical manifestations of ventricular dysfunction while receiving tacrolimus therapy, echocardiographic evaluation should be considered. If myocardial hypertrophy is diagnosed, dosage reduction or discontinuation of tacrolimus should be considered.

Tacrolimus may prolong the QT interval and may cause *Torsades de pointes*. Caution should be exercised in patients with known risk factors for QT prolongation (including but not limited to, congenital or acquired QT prolongation and concomitant medications known to prolong the QT interval or known to increase tacrolimus exposure) (see 9 Drug Interactions).

Driving and Operating Machinery

Tacrolimus may cause visual and neurological disturbances. No studies have been performed on the effects of tacrolimus on the ability to drive and use machines.

Gastrointestinal

Gastrointestinal perforation has been reported in patients treated with tacrolimus, although all cases were considered a complication of transplant surgery or were accompanied by infection, diverticulum, or malignant neoplasm. As gastrointestinal perforation may be serious or life-threatening, appropriate medical/surgical management should be instituted promptly (see 8 Adverse Reactions).

Hematologic

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. A mechanism for tacrolimus induced PRCA has not been elucidated. All patients reported risk

factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medications associated with PRCA. If PRCA is diagnosed, discontinuation of tacrolimus should be considered.

Thrombotic microangiopathy (TMA) (including hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP))

Concurrent use of tacrolimus and mTOR inhibitors may contribute to the risk of thrombotic microangiopathies (TMA) including hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

Hepatic/Biliary/Pancreatic

Advagraf was shown to cause new onset diabetes mellitus in clinical trials of kidney transplant patients. New onset diabetes after transplantation (NODAT) may be reversible in some patients. Black and Hispanic kidney transplant patients are at an increased risk. Blood glucose concentrations should be monitored frequently in patients using Advagraf (see 8 Adverse Reactions).

In *de novo* liver transplant patients, the overall proportion of patients with NODAT as defined by the composite endpoint was 44.8% in the Advagraf group and 44.9% in the Prograf group [Table 4]. The difference between the groups was not statistically significant (P > 0.1) in the 12 month study.

Table 4: Proportion of At-risk Adult *De Novo* Liver Transplant Recipients with NODAT Through 12 Months

	Advagraf (extended-release) / Corticosteroids (n=181)	Prograf (immediate-release) / Corticosteroids (n=185)
Fasting Plasma Glucose ≥ 7 mmol/L	26.0%	24.3%
Insulin Use ≥ 30 days	30.4%	29.2%
Oral Hypoglycemic Use	5.5%	4.9%
HbA _{1c} ≥ 6.5%	9.4%	9.2%

Immune

A lymphoproliferative disorder (LPD) related to Epstein-Barr Virus (EBV) infection has been reported in immunosuppressed organ transplant recipients. The risk of LPD appears greatest in young children who are at risk for primary EBV infection while immunosuppressed or who are switched to Advagraf following long-term immunosuppression therapy. Because of the danger

of oversuppression of the immune system which can increase susceptibility to infection, combination immunosuppressant therapy other than corticosteroids and MMF is not recommended.

Immunosuppressed patients are at increased risk of developing bacterial, viral, fungal, and protozoal infections, including infection reactivation (e.g. Hepatitis B reactivation) and opportunistic infections, including latent viral infections. These include BK virus-associated nephropathy and JC virus-associated progressive multifocal leukoencephalopathy (PML) which have been observed in patients receiving tacrolimus. These infections are often related to a high immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.

Cytomegalovirus (CMV) Infections

CMV is the most frequent opportunistic infection reported with tacrolimus. CMV seronegative transplant patients who receive an organ from a CMV seropositive donor disease are at higher risk of developing CMV viremia and CMV disease.

Monitoring and Laboratory Tests

Serum creatinine, potassium, and fasting glucose should be assessed regularly. Routine monitoring of metabolic and hematologic systems should be performed as clinically warranted.

Blood Concentration Monitoring

Monitoring of tacrolimus blood levels in conjunction with other laboratory and clinical parameters is considered an essential aid to transplant patient management. During the immediate post-operative period, trough blood concentrations should be measured every 1-3 days. Tacrolimus doses are usually reduced in the post-transplant period. In patients with hepatic or renal dysfunction, or in those receiving or discontinuing concomitant interacting medications, more intensive monitoring may be required, since tacrolimus clearance may be affected under each of these circumstances. More frequent monitoring may also be required in patients early after transplantation since it is at this time that the patients experience the highest risk of rejection. Blood concentration monitoring is not a replacement for renal and liver function monitoring and tissue biopsies. Following discharge from the hospital, the frequency of patient monitoring will decrease with time post-transplant.

Methods commonly used for the assay of tacrolimus include high performance liquid chromatography with tandem mass spectrometric detection (HPLC/MS/MS), enzyme immunoassay (EIA), microparticle enzyme immunoassay (MEIA), and enzyme-linked immunosorbent assay (ELISA). Comparison of the concentrations in published literature to patient concentrations using the current assays must be made with detailed knowledge of the assay methods and biological matrices employed. Whole blood is the matrix of choice and specimens should be collected into tubes containing ethylene diamine tetraacetic acid (EDTA)

anti-coagulant. Heparin anti-coagulation is not recommended because of the tendency to form clots on storage. Samples which are not analyzed immediately should be stored at room temperature or in a refrigerator and assayed within 7 days; if samples are to be kept longer, they should be deep frozen at -20°C for up to 12 months.

Data from kidney and liver transplant recipients receiving tacrolimus administered as Prograf (immediate-release formulation) indicate that trough concentrations of tacrolimus in whole blood, as measured by IMx® MEIA (kidney) and ELISA (liver), were most variable during the first week of dosing, and **the relative risk of toxicity is increased with higher whole blood trough concentrations. Therefore, monitoring of whole blood trough concentrations is recommended to assist in the clinical evaluation of toxicity.** Long-term post-transplant patients often are maintained at the low end of the recommended target range. For stable transplant recipients converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation), the same type of therapeutic monitoring can be used.

Kidney

Data from the phase III Advagraf kidney study indicate that trough concentrations of tacrolimus in whole blood were most variable during the first week of dosing. By month 2, 76% of the patients had trough concentrations between 7 – 16 ng/mL, and greater than 78% maintained concentrations between 5 – 15 ng/mL, from month 4 through 1 year.

Liver

Data from a phase III study with Advagraf in *de novo* liver transplant recipients indicate that trough concentrations of tacrolimus in whole blood were most variable during the first week post-transplantation. Mean trough concentrations from this study were 11.40 ng/mL for months 1 and 8.40 ng/mL for month 6 and 7.60 ng/mL for month 12 post-transplantation.

Neurologic

Tacrolimus can cause neurotoxicity, particularly when used in high doses. Nervous system disorders, including tremor, headache, and other changes in motor function, mental status, and sensory function were reported in 63.1% of *de novo* kidney transplant recipients. Tremor occurred in 35.0% of Advagraf-treated kidney transplant patients compared to 19.8% of Neoral-treated kidney transplant patients. The incidence of other neurological events in kidney transplant patients was similar in the two treatment groups (see 8 Adverse Reactions). Tremor and headache have been associated with high whole blood concentrations of tacrolimus and may respond to dosage adjustment. Seizures have occurred in adult and pediatric patients receiving tacrolimus as Prograf (immediate-release formulation). Coma and delirium also have been associated with high plasma concentrations of tacrolimus received as Prograf (immediate-release formulation).

Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). Symptoms indicating PRES include headache, altered mental status, seizures, visual disturbances. Diagnosis should be confirmed by radiological procedure (e.g., MRI). If PRES is suspected or diagnosed, blood pressure and seizure control and

immediate discontinuation of immunosuppression is advised. Most patients completely recover after appropriate measures are taken.

Renal

Tacrolimus can cause nephrotoxicity, particularly when used in high doses. Renal and urinary disorders were reported in 36.9% of *de novo* kidney transplantation patients and 50% of *de novo* liver transplantation patients receiving Advagraf. In *de novo* kidney transplant recipients, increased creatinine was reported in 18.7% of Advagraf-treated patients and 22.6% of Neoral-treated patients (see 8 Adverse Reactions). Tacrolimus can result in renal function impairment in post-transplant patients. Acute renal impairment without active intervention may progress to chronic renal impairment. Patients with impaired renal function should be monitored closely as the dosage of tacrolimus may need to be reduced. The risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with drugs associated with nephrotoxicity (see 9 Drug Interaction). When concurrent use of tacrolimus with other known nephrotoxic drugs is required, monitor renal function and tacrolimus blood concentrations frequently, and dose adjustments of both tacrolimus and/or concomitant medications should be considered upon initiation, throughout concurrent treatment and at discontinuation of such concomitant drugs. **In particular, to avoid excess nephrotoxicity, when switching patients from a cyclosporine-based regimen to an Advagraf-based regimen, cyclosporine should be discontinued at least 24 hours prior to initiating Advagraf. Advagraf dosing may be further delayed in the presence of elevated cyclosporine levels (see 9 Drug Interactions – 9.4 Drug-Drug Interactions – Drug Interactions Potentially Affecting Renal Function). When switching from tacrolimus to cyclosporine, tacrolimus should be discontinued for at least 24 hours before initiating the other medication.**

Mild to severe hyperkalemia was reported in 22.0% of kidney *de novo* transplant recipients treated with Advagraf and may require treatment (see 8 Adverse Reactions). **Serum potassium levels should be monitored. Potassium-sparing diuretics should not be used and high intake of potassium should be avoided during Advagraf therapy (see 7 Warnings and Precautions – Cardiovascular, Monitoring and Laboratory Tests).**

The use of Advagraf (extended-release formulation) in liver transplant recipients experiencing post-transplant hepatic impairment may be associated with increased risk of developing renal insufficiency related to high whole blood levels of tacrolimus. These patients should be monitored closely and dose adjustment should be considered (see 4 Dosage and Administration).

Reproductive Health: Female and Male Potential

- **Fertility**

In reproduction studies in rats and rabbits, adverse effects on the fetus were observed mainly at dose levels that were toxic to dams. However, in female rats dosed during organogenesis,

embryo toxicity (expressed as reduced pup weights) was seen at a dose which was one-third of the maternally toxic dose. At this same dose, when administered prior to mating and during gestation, tacrolimus was associated with adverse effects on female reproductive parameters and embryo lethality. This dose was equivalent to 0.5X the clinical dose. (See 7 Warnings and Precautions – Special Populations).

7.1 Special Populations

7.1.1 Pregnant Women

Advagraf (extended-release formulation) should not be used during pregnancy unless the potential benefit to the mother outweighs potential risk to the fetus (See **16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicity**). There are no adequate and well-controlled studies in pregnant women.

Tacrolimus is transferred across the placenta and infants exposed to tacrolimus *in utero* may be at a risk of prematurity, birth defects/congenital anomalies, low birth weight, and fetal distress. The use of tacrolimus during pregnancy has been associated with preterm delivery, neonatal hyperkalemia and renal dysfunction.

Tacrolimus may increase hyperglycemia in pregnant women with diabetes (including gestational diabetes). Monitor maternal blood glucose levels regularly.

Tacrolimus may exacerbate hypertension in pregnant women and increase pre-eclampsia. Monitor and control blood pressure. Females and males of reproductive potential should consider the use of appropriate contraception prior to starting treatment with tacrolimus.

7.1.2 Breast-feeding

Tacrolimus is excreted in human milk. The effects of tacrolimus on the breastfed infant, or on milk production have not been assessed. As detrimental effects on the newborn cannot be excluded, women should not breastfeed while receiving tacrolimus.

7.1.3 Pediatrics

Heart failure, cardiomegaly and increased thickness of the myocardium have been reported in patients taking tacrolimus.

7.1.4 Geriatrics

No formal studies have been performed to evaluate the effect of tacrolimus specifically in the geriatric population.

Forty-three patients ≥ 65 years of age have been treated with Advagraf in phase II and III studies in solid organ transplantation; there were no patient deaths or graft failures in these patients. Two of these 43 patients experienced acute rejection. No overall differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. In general, dose selection for an

elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The most common adverse reactions reported were infection, tremor, hypertension, decreased renal function, constipation, diarrhea, headache, abdominal pain and insomnia. Many of these adverse reactions were mild and responded to a reduction in dosage. Insulin-dependent post-transplant diabetes mellitus (PTDM) was related to increased whole blood trough concentrations of tacrolimus and higher doses of corticosteroids. The median time to onset of PTDM was 68 days.

8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Kidney

In a large (n=668), phase III, randomized, comparative trial, *de novo* kidney transplant recipients received either Advagraf (extended-release formulation) plus mycophenolate mofetil (MMF) or Prograf (immediate-release formulation) plus MMF or Neoral plus MMF. All three regimens included corticosteroids and basiliximab induction. The incidence of adverse events that occurred in $\geq 15\%$ of Advagraf-treated *de novo* kidney transplant recipients is shown in Table 5 below.

Table 5: De Novo Kidney Transplantation: Adverse Events Occurring in $\geq 15\%$ of Advagraf (tacrolimus extended-release capsules) + MMF Treated Patients

	Prograf (immediate-release) + MMF N = 212 (% Patients)	Advagraf (extended-release) + MMF N = 214 (% Patients)	Neoral + MMF N = 212 (% Patients)
Gastrointestinal Disorders			
Diarrhea	44.3%	45.3%	25.5%
Nausea	38.7%	42.1%	46.7%
Constipation	35.8%	41.6%	41.0%
Vomiting	25.5%	26.2%	24.5%
Dyspepsia	17.9%	15.0%	15.1%

	Prograf (immediate-release) + MMF N = 212 (% Patients)	Advagraf (extended-release) + MMF N = 214 (% Patients)	Neoral + MMF N = 212 (% Patients)
Injury, Poisoning and Procedural Complications			
Post-procedural pain	28.8%	29.4%	27.4%
Incision site complication	28.3%	20.6%	23.1%
Metabolism and Nutritional Disorders			
Hypomagnesemia	28.3%	25.7%	22.2%
Hypophosphatemia	27.8%	23.8%	21.2%
Hyperkalemia	25.5%	22.0%	19.3%
Hyperglycemia	21.2%	19.2%	15.1%
Hyperlipidemia	17.5%	16.4%	24.5%
Hypokalemia	16.0%	15.9%	17.5%
Infections and Infestations			
Urinary tract infection	25.5%	15.9%	22.2%
General Disorders and Administration Site Conditions			
Edema peripheral	34.9%	35.5%	45.8%
Fatigue	10.8%	15.9%	12.3%
Nervous System Disorder			
Tremor	34.4%	35.0%	19.8%
Headache	24.1%	21.5%	24.5%
Investigations			
Blood creatinine increased	23.1%	18.7%	22.6%
Blood and Lymphatic System Disorders			
Anemia	30.2%	33.6%	27.8%
Leukopenia	15.6%	16.4%	11.8%

	Prograf (immediate-release) + MMF N = 212 (% Patients)	Advagraf (extended-release) + MMF N = 214 (% Patients)	Neoral + MMF N = 212 (% Patients)
Vascular Disorders			
Hypertension	32.1%	29.9%	34.9%
Musculoskeletal and Connective Tissue Disorders			
Back pain	12.7%	15.0%	14.2%
Psychiatric Disorders			
Insomnia	30.2%	25.7%	21.2%

Liver

In a phase III (n=467), randomized, double-blind comparative trial, *de novo* liver transplant recipients received either Advagraf (0.2 mg/kg/day) or Prograf (0.1 mg/kg/day in two divided doses). Both regimens included corticosteroids. The incidence of adverse events that occurred in $\geq 15\%$ of Advagraf-treated *de novo* liver transplant recipients is shown in Table 6. The most common events among recipients who received Advagraf ($\geq 15\%$ of patients in the Advagraf group) were anemia, diarrhea, hyperglycemia, hypertension, pleural effusion, pyrexia, renal insufficiency and thrombocytopenia.

Table 6: *De novo* liver transplantation: Adverse events occurring in $\geq 15\%$ of Advagraf or Prograf-treated patients incidence of most frequently reported adverse events regardless of relationship to study medication

	Advagraf (N=237) Patients (%)	Prograf (N=234) Patients (%)
Blood and lymphatic system disorders		
Anaemia	31.2%	30.8%
Thrombocytopenia	15.2%	16.2%
Gastrointestinal disorders		
Diarrhea	24.9%	18.4%
General disorders and administration site conditions		
Pyrexia	17.3%	17.5%

	Advagraf (N=237) Patients (%)	Prograf (N=234) Patients (%)
Metabolism and nutrition disorders		
Hyperglycaemia	18.6%	22.6%
Renal and urinary disorders		
Renal insufficiency	24.5%	23.1%
Respiratory, thoracic and mediastinal disorders		
Pleural effusion	15.2%	17.9%
Vascular disorders		
Hypertension	30.8%	32.5%

The following adverse events were also reported in clinical studies of solid organ transplant recipients who were treated with Advagraf at a frequency of $\geq 3\%$ to $< 15\%$.

Blood and Lymphatic System Disorders: leukopenia, secondary anemia, leukocytosis, pancytopenia;

Cardiac Disorders: atrial fibrillation, tachycardia;

Gastrointestinal Disorders: abdominal pain, abdominal pain upper, ascites, constipation, dyspepsia, flatulence, gastroenteritis, nausea, vomiting;

General Disorders and Administration Site Conditions: asthenia, chest pain, edema, peripheral edema, pyrexia, pain;

Hepatobiliary Disorders: bile duct stenosis, cholestasis, cytolytic hepatitis, hepatic artery stenosis, hyperbilirubinemia;

Infections and Infestations: bacterial urinary tract infection, bacterial pneumonia, bacterial sepsis, biliary tract infection, cytomegalovirus infection, hepatitis C, herpes simplex, influenza, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, wound infection;

Injury, Poisoning and Procedural Complications: graft dysfunction, incision site complication, necrotic preservation injury or graft, post-procedural bile leak;

Investigations: abnormal liver function test, increased blood glucose, increased blood creatinine, hepatic enzyme increased, hepatitis C virus;

Metabolism and Nutrition Disorders: dehydration, metabolic acidosis, hyperkalemia, hyperuricemia, noninsulin-dependent diabetes mellitus, hypoalbuminemia, hypocalcemia, hypokalemia, diabetes mellitus, hypomagnesemia, hyperlipidemia, hyponatremia, insulin-dependent diabetes mellitus;

Musculoskeletal and Connective Tissue Disorders: arthralgia, back pain, muscle spasm, pain in extremity including Calcineurin-Inhibitor Induced Pain Syndrome (CIPS);

Nervous System Disorders (see 7 Warnings and Precautions): dizziness, tremor, headache;

Psychiatric Disorders: agitation, anxiety, depression, confusional state, insomnia, psychotic disorder;

Renal and Urinary Disorders (see 7 Warnings and Precautions): acute renal failure, hematuria, oliguria, renal impairment, renal insufficiency;

Respiratory, Thoracic and Mediastinal Disorders: cough, dyspnea, pharyngolaryngeal pain, respiratory failure;

Skin and Subcutaneous Tissue Disorders: acne, pruritus;

Vascular Disorders: hypotension, hemorrhage.

8.3 Less Common Clinical Trial Adverse Reactions

The following adverse events were reported in clinical trials of solid organ transplant recipients treated with Advagraf at a frequency rate of $\geq 1\%$ and $< 3\%$:

Blood and Lymphatic System Disorders: bone marrow depression, coagulopathy, neutropenia, febrile neutropenia, polycythemia, thrombocytopenia;

Cardiac Disorders: cardiac failure;

Eye Disorders: vision blurred;

Gastrointestinal Disorders: abdominal discomfort, abdominal distension, abdominal pain lower, gastritis, gastroesophageal reflux disease, hemorrhoids, hernial eventration, loose stools, esophagitis, post-procedural nausea, toothache, umbilical hernia;

General Disorders and Administration Site Conditions: anasarca, chest discomfort, fatigue, multi-organ failure, impaired healing, rigors;

Hepatobiliary Disorders: hepatic artery thrombosis, hepatic steatosis, hepatic fibrosis, hepatic function abnormal, jaundice;

Infections and Infestations: ascites infection, bacterial infections, bronchitis, candidiasis, cellulitis, diarrhea infections, Escherichia urinary tract infection, fungal infection, herpes zoster, herpes virus infection, human polyomavirus infection, liver abscess, lower respiratory tract infection, oral candidiasis, pharyngeal candidiasis, pharyngitis, pyelonephritis, respiratory moniliasis, respiratory tract infection, respiratory tract infection bacterial, sepsis, upper respiratory fungal infection;

Injury, Poisoning, and Procedural Complications: anemia postoperative, anastomotic stenosis, complications of transplant surgery, contusion, drug toxicity, fall, hepatic hematoma, incisional hernia, overdose, post-procedural discharge, procedural hypotension, post-procedural hemorrhage, post-procedural pain, therapeutic agent toxicity, wound dehiscence, wound secretion;

Investigations: blood alkaline phosphatase increased, blood bilirubin increased, blood glucose fluctuation, blood magnesium decreased, blood phosphorus decreased, blood potassium decreased, c-reactive protein increased, cardiac murmur, drug level decreased, drug level increased, gamma-glutamyltransferase increased, international normalized ratio increased, platelet count decreased, urine output decreased, weight decreased, weight increased, white blood cell count increased;

Metabolism and Nutrition Disorders: acidosis, anorexia, decreased appetite, dehydration, dyslipidemia, fluid overload, glucose tolerance impaired, gout, hypercalcemia, hypercholesterolemia, hyperhomocysteinemia, hyperphosphatemia, hypophosphatemia, hypoglycemia, hypertriglyceridaemia;

Musculoskeletal and Connective Tissue Disorders: joint swelling, myalgia, osteopenia, osteoporosis;

Nervous System Disorders: convulsion, disturbance in attention, hypoesthesia, neurotoxicity, neuropathy, neuropathy peripheral, paraesthesia;

Psychiatric Disorders: delirium, hallucination, restlessness;

Renal and Urinary Disorders: dysuria, nephropathy toxic, proteinuria, pollakiuria, renal cyst, urethral pain;

Reproductive System and Breast Disorders: erectile dysfunction, prostatic hypertrophy;

Respiratory, Thoracic and Mediastinal Disorders: atelectasis, dyspnea exertional, epistaxis, hydrothorax, lung disorder, nasal congestion, pneumothorax, productive cough, pulmonary edema;

Skin and Subcutaneous Tissue Disorders: alopecia, ecchymosis, hyperhidrosis, night sweats, rash, skin lesion, scar pain;

Vascular Disorders: hematoma, hemodynamic instability, hot flush, orthostatic hypotension.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Not Applicable.

8.5 Post-Market Adverse Reactions

The following adverse events have been reported from worldwide marketing experience with tacrolimus (Advagraf [extended-release formulation] and/or Prograf [immediate-release formulation]). Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, or (3) strength of causal connection to the drug:

Blood and Lymphatic System Disorders: agranulocytosis, disseminated intravascular coagulation, eosinophilia, febrile neutropenia, hemolytic anemia, hemolytic-uremic syndrome, pure red cell aplasia, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombotic microangiopathy;

Cardiac Disorders: atrial flutter, cardiac arrhythmia, cardiac arrest, cardiac disorder, congestive cardiomyopathy, electrocardiogram T wave abnormal, myocardial infarction, myocardial ischemia, pericardial effusion, QT prolongation with or without *Torsades de pointes*, venous thrombosis deep limb, ventricular extrasystoles, ventricular fibrillation;

Ear and Labyrinth Disorders: hearing loss including deafness, tinnitus;

Endocrine Disorders: hypothyroidism;

Eye Disorders: blindness, blindness cortical, diplopia, eyelid edema, optic neuropathy, photophobia;

Gastrointestinal Disorders: colitis, enterocolitis, gastrointestinal obstruction, gastrointestinal perforation, granulomatous liver disease, hepatocellular injury, impaired gastric emptying, liver fatty, mouth ulceration, Mikulicz's syndrome, pancreatitis hemorrhagic, pancreatitis necrotizing, stomach ulcer;

General Disorders and Administration Site Conditions: disease recurrence, drug effect delayed, drug effect increased, drug ineffective, drug interaction, drug intolerance, fatigue, feeling of body temperature change, feeling jittery, hot flushes, mobility decreased, multi-organ failure, thirst;

Hepatobiliary Disorders: cholestasis of pregnancy, hepatic cytolysis, hepatic necrosis, hepatotoxicity, venoocclusive liver disease;

Infections and Infestations: eczema infected, Escherichia, urinary tract infection, BK virus associated nephropathy;

Injury, Poisoning and Procedural Complications: drug dispensing error, drug prescribing error, maternal exposure during pregnancy, medication error, primary graft dysfunction;

Investigations: blood urea increased, drug level below therapeutic, drug level fluctuating, immunosuppressant drug level decreased, platelet count increased, transaminases increased;

Metabolism and Nutrition Disorder: appetite disorder, diabetes mellitus inadequate control, glycosuria, hyperammonaemia, amylase increased, ketoacidosis;

Musculoskeletal and Connective Tissue Disorders: immunoglobulin G4 related sclerosing disease, muscular weakness;

Neoplasms benign, malignant and unspecified (including cysts and polyps): breast cancer, haematological malignancy, hepatic neoplasm malignant, lung neoplasm malignant, pharyngeal cancer stage unspecified;

Nervous System Disorders: aphasia, balance disorder, brachial plexopathy, carpal tunnel syndrome, cerebrovascular accident, cerebral infarction, encephalopathy, hemiparesis, incoherent, leukoencephalopathy, mononeuropathy multiplex, mutism, neuralgia, neurotoxicity, paraesthesia, peripheral nerve lesion, peripheral sensory neuropathy, polyneuropathy, posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML), quadriplegia, somnolence, speech disorder, syncope, tremor;

Psychiatric Disorders: intentional drug misuse, mental disorder;

Renal and Urinary Disorders: albuminuria, cystitis hemorrhagic, glycosuria, hemolytic-uremic syndrome, micturition disorder, renal failure, renal failure chronic;

Respiratory, Thoracic and Mediastinal Disorders: acute pulmonary edema, acute respiratory distress syndrome, interstitial lung disease, lung infiltration, respiratory distress;

Skin and Subcutaneous Tissue Disorders: dermatosis, Stevens-Johnson syndrome, toxic epidermal necrolysis;

Vascular Disorders: flushing.

There have been rare spontaneous reports of myocardial hypertrophy associated with clinically manifested ventricular dysfunction in patients receiving Prograf (immediate-release

formulation) therapy (see 7 Warnings and Precautions).

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Tacrolimus is extensively metabolized by the mixed-function oxidase system, primarily the cytochrome P450 system (CYP3A). Tacrolimus dose reductions and prolongation of dosing interval may be required in order to maintain similar tacrolimus exposure when co-administered with strong CYP3A4 inhibitors. Drugs known to induce these enzyme systems may result in an increased metabolism of tacrolimus or decreased bioavailability as indicated by decreased whole blood or plasma concentrations, thereby potentially requiring dose increases in order to maintain similar tacrolimus exposure when co-administered with strong CYP3A4 inducers (Refer to Table 7). Close monitoring of tacrolimus blood levels, renal function and other side effects (including ECG monitoring for QT prolongation) is strongly recommended when administered with strong CYP3A4 inhibitors (see **4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dose Adjustment**, and **7 WARNINGS AND PRECAUTIONS, General**).

9.3 Drug-Behavioural Interactions

As with other immunosuppressive agents, owing to the potential risk of malignant skin changes, exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using sunscreen with a high protection factor.

9.4 Drug-Drug Interactions

Drug Interactions Potentially Affecting Renal Function

Due to the potential for additive or synergistic impairment of renal function, care should be taken when administering Advagraf with drugs that may be associated with renal dysfunction. These include, but are not limited to, aminoglycosides, amphotericin B, ganciclovir, acyclovir and cisplatin. NSAIDs may interact with Advagraf causing deteriorations in blood pressure (BP) control and serum creatinine levels. The half-life of cyclosporine has been shown to increase when tacrolimus is given simultaneously. Initial clinical experience with Prograf (immediate-release formulation) and cyclosporine resulted in additive/synergistic nephrotoxicity when both agents were co-administered. For these reasons, the combined administration of cyclosporine and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received cyclosporine. Patients switched from cyclosporine to Advagraf should receive the first Advagraf dose no sooner than 24 hours after the last cyclosporine dose. Dosing may be further delayed in the presence of elevated cyclosporine levels.

Drug Interactions Potentially Affecting Tacrolimus Blood Concentrations

Since tacrolimus is metabolized mainly by the CYP3A (cytochrome P450 3A) enzyme systems, substances known to inhibit these enzymes may decrease the metabolism or increase bioavailability of tacrolimus with resultant increases in whole blood or plasma concentrations. Drugs known to induce these enzyme systems may result in an increased metabolism of tacrolimus or decreased bioavailability as indicated by decreased whole blood or plasma concentrations.

Rapid increase in tacrolimus levels may occur when co-administered with CYP3A4 inhibitors. Early, within the first few days of co-administration, and frequent continued monitoring of tacrolimus blood levels, as well as monitoring for renal function, for QT prolongation with ECG, and for other side effects is strongly recommended.

Monitoring of blood concentrations and appropriate dosage adjustments are essential when such drugs (Table 7) are used concomitantly with tacrolimus.

Table 7: Established or Potential Drug-Drug Interactions

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
Antacid: magnesium-aluminium-hydroxide	CT	↑ tacrolimus	In a single-dose crossover study in healthy volunteers, co-administration of tacrolimus (administered as Prograf [immediate-release formulation]) and magnesium-aluminium-hydroxide resulted in a 21% increase in the mean tacrolimus AUC and a 10% decrease in the mean tacrolimus C_{max} relative to tacrolimus administration alone.
Anti-Arrhythmic Agent: amiodarone [†]	T	↑ tacrolimus	The concomitant use of Prograf with amiodarone may lead to increased levels of tacrolimus and/or a potential pharmacodynamic interaction based on displacement of amiodarone from its plasma protein binding site. [†] When co-administered with amiodarone, dose adjustment may be required in most patients.

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
Azole antifungals: ketoconazole [†]	CT	↑ tacrolimus	<p>In a study of 24 healthy male volunteers, co-administration of a 4 mg Advagraf dose with ketoconazole (400 mg/day) increased the mean AUC_{inf} and C_{max} of tacrolimus by 645% and 356%, respectively.</p> <p>In a study of 6 normal volunteers, a significant increase in tacrolimus (administered as Prograf [immediate-release formulation]) oral bioavailability (14 ± 5% vs 30 ± 8%) was observed with concomitant administration of ketoconazole (200 mg), a strong CYP3A4 and P-glycoprotein inhibitor. The apparent clearance of oral tacrolimus during ketoconazole administration was significantly decreased compared to tacrolimus alone (0.430±0.129 L/hr/kg vs. 0.148±0.043 L/hr/kg). Overall, clearance of IV tacrolimus was not significantly changed by ketoconazole co-administration, although it was highly variable between patients.</p> <p>[†]When co-administered with ketoconazole, a dose adjustment of tacrolimus is required in most patients.</p>
Azole antifungals, cont'd: clotrimazole fluconazole [‡] itraconazole [‡] voriconazole [‡]	T	↑ tacrolimus	<p>The concomitant use of Advagraf with azole antifungals that are strong or moderate CYP3A4 and P-glycoprotein inhibitors (e.g. itraconazole, fluconazole, voriconazole) might lead to an increased Advagraf concentration.</p> <p>[‡]When co-administered with fluconazole, itraconazole and</p>

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
			voriconazole, a dose adjustment of tacrolimus is required in most patients.
Calcium channel blockers: diltiazem nicardipine nifedipine verapamil	T	↑ tacrolimus	Co-administration of substrates and/or inhibitors of CYP3A4 and P-glycoprotein with Advagraf might increase blood concentrations of tacrolimus.
GI Prokinetic Agents: cisapride* metoclopramide	T	↑ tacrolimus	Co-administration of Advagraf with substrates of CYP3A4 might increase blood concentrations of tacrolimus.
Macrolide antibiotics: erythromycin‡‡ clarithromycin‡ troleandomycin	T	↑ tacrolimus	<p>Co-administration of Advagraf with substrates and/or inhibitors of CYP3A4 and P-glycoprotein might increase blood concentrations of tacrolimus.</p> <p>‡ Cases have been reported in which a sharp rise in tacrolimus levels occurred very rapidly, as early as within 1-3 days after co-administration with clarithromycin despite an immediate reduction of tacrolimus dose. Early, within the first few days of co-administration, and frequent continued monitoring of tacrolimus whole blood trough levels within 1-3 days is strongly recommended when co-administered with strong CYP3A4 inhibitors.</p> <p>‡‡When co-administered with erythromycin, a dose adjustment of tacrolimus is required in most patients.</p>

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
Proton pump inhibitor: lansoprazole omeprazole	T	↑ tacrolimus	Lansoprazole and omeprazole (CYP2C19 and CYP3A4 substrate, inhibitor) may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby substantially increase tacrolimus whole blood concentrations, especially in transplant patients who are intermediate or poor CYP2C19 metabolizers, as compared to those patients who are efficient CYP2C19 metabolizers.
Other drugs: bromocriptine cimetidine chloramphenicol cyclosporine danazol ethinyl estradiol methylprednisolone nefazodone	T	↑ tacrolimus	Co-administration of Advagraf with substrates and/or inhibitors of CYP3A4 and P-glycoprotein might increase blood concentrations of tacrolimus.
Protease Inhibitors: boceprevir nelfinavir ritonavir saquinavir telaprevir	CT	↑ tacrolimus	Interaction studies with drugs used in HIV/HCV therapy have not been conducted. However, care should be exercised when drugs that are metabolized by CYP3A4 (for example but not limited to boceprevir, nelfinavir, ritonavir, saquinavir, telaprevir) are administered concomitantly with tacrolimus. In a single dose study in 9 healthy volunteers, co-administration of tacrolimus (0.5 mg single dose) with telaprevir (750 mg TID for 13 days)

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
			<p>increased tacrolimus dose-normalized C_{max} by 9.3-fold and AUC by 70-fold. In a single dose study in 12 subjects, co-administration of tacrolimus (0.5 mg single dose) with boceprevir (800 mg three times daily for 11 days) increased tacrolimus C_{max} by 9.9-fold and AUC by 17-fold compared to tacrolimus alone.</p> <p>Based on a clinical study of 5 liver transplant recipients, co-administration of tacrolimus (administered as Prograf [immediate-release formulation]) with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.</p> <p>Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when used concomitantly with protease inhibitors.</p>
Cytomegalovirus (CMV) antivirals: letermovir	CT	↑ tacrolimus	Co-administration of Advagraf with letermovir may result in clinically relevant increases in the plasma concentrations of Advagraf. Monitor blood concentrations and if needed make appropriate dosage adjustments when letermovir is used concomitantly with tacrolimus.
Anticonvulsants: carbamazepine	T	↓ tacrolimus	Co-administration of Advagraf with inducers of CYP3A4 and P-glycoprotein

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
phenobarbital phenytoin ^{††}			<p>might decrease blood concentrations of tacrolimus.</p> <p>^{††}When co-administered with phenytoin, a dose adjustment of tacrolimus is required in most patients.</p>
Anti-Infectives: Rifampicin ^{**}	CT	↓ tacrolimus	<p>In a study of 28 healthy male volunteers, co-administration of a single 10 mg Advagraf dose with rifampicin (600 mg/day) decreased mean AUC_{inf} and C_{max} of tacrolimus by 56% and 46%, respectively.</p> <p>In a study of 28 healthy male volunteers, co-administration of a single 10 mg Advagraf dose and two 5 mg Prograf doses with rifampicin (600 mg/day) decreased mean AUC_{inf} and C_{max} of tacrolimus by 56% and 46%, respectively.</p> <p>In a study of 6 normal volunteers, a significant decrease in tacrolimus (administered as Prograf [immediate-release formulation]) oral bioavailability (14 ± 6% vs 7 ± 3%) was observed with concomitant administration of rifampicin (600 mg), a strong CYP3A4 and P-glycoprotein inducer. In addition, there was a significant increase in tacrolimus clearance (0.036 ± 0.008 L/hr/kg vs. 0.053 ± 0.010 L/hr/kg) with concomitant rifampicin administration.</p> <p>In a study of 9 normal volunteers, concomitantly administered 10 mL doses of aluminum hydroxide or milk of magnesia antacids did not affect the</p>

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
			rate and extent of absorption of orally administered tacrolimus, as indicated by C_{max} , T_{max} and AUC_{0-t} . **When co-administered with rifampicin, a dose adjustment of tacrolimus is required in most patients.
Anti-infectives, cont'd: rifabutin	T	↓ tacrolimus	Co-administration of Advagraf with inducers of CYP3A4 and P-glycoprotein might decrease blood concentrations of tacrolimus.
Anti-infectives, cont'd: caspofungin	T	↓ tacrolimus	Caspofungin reduced the blood AUC_{0-12} of tacrolimus by approximately 20%, peak blood concentration (C_{max}) by 16%, and 12-hour blood concentration (C_{12hr}) by 26% in healthy adult subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10 th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
Calcineurin inhibitor: Sirolimus	CT	↓ tacrolimus	Following 14 days co-administration of tacrolimus (administered as Prograf [immediate-release formulation]) and sirolimus (2 mg/day or 5 mg/day; a substrate for both CYP3A4 and P-glycoprotein) in stable renal transplant patients, tacrolimus AUC and C_{min} decreased approximately 30% relative to tacrolimus alone. Mean tacrolimus AUC_{0-12} and C_{min} following co-administration of 1 mg/day of sirolimus decreased approximately 3% and 11%, respectively. The safety and

Concomitant Drug Class: Drug Name	Reference	Effect on concentration of tacrolimus	Comment
			efficacy of the use of tacrolimus with sirolimus has not been established.
Direct-acting antiviral (DAA): Sofosbuvir	T	↓ or ↑ Tacrolimus	The pharmacokinetics of tacrolimus may be impacted by changes in liver function during DAA therapy, related to clearance of HCV virus. Impact on tacrolimus concentration may vary depending on the combination of DAA drugs used. A close monitoring and potential dose adjustment of tacrolimus is warranted to ensure continued efficacy and safety.
Herbal preparations: St. John's wort	T	↓ tacrolimus	St. John's wort (<i>Hypericum perforatum</i>) induces CYP3A4 and P-glycoprotein. Since tacrolimus is a substrate for CYP3A4, there is the potential that the use of St. John's wort in patients receiving Advagraf could result in reduced tacrolimus levels.
<i>Schisandra sphenanthera</i> extracts	T	↑ tacrolimus	Co-administration of Advagraf with substrates and/or inhibitors of CYP3A4 and P-glycoprotein might increase blood concentrations of tacrolimus.
Cannabidiol	T	↑ tacrolimus	Co-administration of Advagraf with cannabidiol might increase blood concentrations of tacrolimus. Monitor tacrolimus whole blood trough concentrations and adjust the Advagraf dose if needed.

*No longer marketed in Canada CT=Clinical Trial T=Theoretical.

Advagraf and Vaccinations

Immunosuppressants may affect vaccination. Therefore, during treatment with Advagraf, vaccination may be less effective. The use of live vaccines should be avoided; live vaccines may include, but are not limited to, measles, mumps, rubella, oral polio, BCG, yellow fever and TY 21a typhoid.

Lack of Drug Interaction with Advagraf

At a given mycophenolate mofetil (MMF) dose, mycophenolic acid (MPA) exposure is higher with tacrolimus (administered as Prograf [immediate-release formulation]) co-administration than with cyclosporine co-administration due to the inhibitory action of cyclosporine on biliary excretion of MPA-glucuronide by MRP-2 and the resulting reduction in enterohepatic recirculation of MPA. As a result, exposure to MPA when mycophenolate mofetil is given in combination with cyclosporine is approximately 30-40% lower than that observed when given alone or with tacrolimus. No effect on enterohepatic MPA-glucuronide recirculation is exerted by tacrolimus; thus, clinicians should be aware that there is a potential for increased MPA exposure after crossover from cyclosporine to tacrolimus in patients concomitantly receiving MMF or mycophenolate sodium (MPS). Conversely, there is a potential for decreased MPA exposure after crossover from tacrolimus to cyclosporine in patients concomitantly receiving MMF or MPS. Therapeutic drug monitoring of MPA is recommended.

9.5 Drug-Food Interactions

Grapefruit juice inhibits P450 3A-mediated metabolism and should be avoided.

9.6 Drug-Herb Interactions

St. John's wort (*Hypericum perforatum*) induces CYP3A4 and P-glycoprotein. Since tacrolimus is a substrate for CYP3A4, there is the potential that the use of St. John's wort in patients receiving Advagraf could result in reduced tacrolimus levels.

Schisandra sphenanthera extracts inhibit CYP3A4 and P-glycoprotein and may increase blood concentrations of tacrolimus.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Tacrolimus, the active ingredient in Advagraf, is a macrolide immunosuppressant produced by *Streptomyces tsukubaensis*.

Tacrolimus prolongs the survival of the host and transplanted graft in animal transplant models of liver, kidney, heart, bone marrow, small bowel and pancreas, lung and trachea, skin, cornea, and limb.

In animals, tacrolimus has been demonstrated to suppress some humoral immunity and, to a greater extent, cell-mediated reactions such as allograft rejection, delayed-type hypersensitivity, collagen-induced arthritis, experimental allergic encephalomyelitis, and graft versus host disease.

Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action is not known. Experimental evidence suggests that tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition of T-lymphocyte activation (i.e., immunosuppression).

10.2 Pharmacodynamics

See 10 CLINICAL PHARMACOLOGY, 10.1 Mechanism of Action.

10.3 Pharmacokinetics

Tacrolimus activity is primarily due to the parent drug. The pharmacokinetic parameters of tacrolimus have been determined following oral administration of Advagraf in healthy volunteers, and in kidney and liver transplant recipients (Table 8).

Table 8: Pharmacokinetic Parameters of Advagraf (tacrolimus extended-release capsules)

Population	N	Dose	Day ^s	Pharmacokinetic Parameters		
				C _{max} [‡] (ng/mL)	T _{max} [†] (hr)	AUC ₀₋₂₄ [‡] (ng•hr/mL)
Healthy Volunteers	24	4 mg	Day 1	6.2	2.0	74.3
			Day 10	11.6	2.0	155.0
Adult Kidney <i>De Novo</i>	34	0.19 mg/kg	Day 1	18.2	3.0	231.9
		0.20 mg/kg	Day 14	29.9	2.0	363.9
Adult Kidney Conversion	66	5.8 mg	Day 1	14.8	2.0	204.6
		6.1 mg	Day 14	14.2	2.0	197.6

Population	N	Dose	Day [§]	Pharmacokinetic Parameters		
				C _{max} [‡] (ng/mL)	T _{max} [†] (hr)	AUC ₀₋₂₄ [‡] (ng•hr/mL)
Adult Liver <i>De Novo</i>	45	0.12 mg/kg	Day 1	8.8	4.0	114
		0.22 mg/kg	Day 14	23.4	2.0	305
Adult Liver Conversion	62	5.2 mg	Day 14	12.5	2.0	177
Pediatric Liver Conversion	18	5.4 mg	Day 7	14.2	2.0	181

Dose is the group mean once daily dose (transplant patients) or the actual administered dose (healthy volunteers). Conversion refers to 1:1 (mg:mg) conversion from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) on a total daily dose basis.

† Median values

‡ Arithmetic means

§ Day of Advagraf treatment.

There was a marked reduction of intra-subject variability for exposure (AUC₀₋₂₄) in Black kidney transplant recipients at steady state after converting from Prograf (immediate-release formulation) (% coefficient of variation; %CV: 25.4%) to Advagraf (extended-release formulation) (% CV: 12.2%). In white kidney transplant recipients, the intra-subject variability for exposure at steady state was similar after converting from Prograf (immediate-release formulation) (% CV: 12.2%) to Advagraf (extended-release formulation) (% CV: 14.1%).

There was a statistically significant reduction (P=0.044) of intra-patient variability for dose adjusted exposure (AUC₂₄) in liver transplant recipients at steady state after converting from Prograf (%CV: 15%) to Advagraf (%CV: 12%).

Due to intersubject variability in tacrolimus pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy (see 4 Dosage and Administration). Pharmacokinetic data indicate that whole blood concentrations rather than plasma concentrations serve as the more appropriate sampling compartment to describe tacrolimus pharmacokinetics.

Absorption

Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable.

In 20 healthy subjects, oral administration of an aqueous suspension of Advagraf was associated with a 5% higher AUC_{0-inf} and a 30% higher C_{max} compared with oral administration of intact capsules; administration of the aqueous suspension via nasogastric tube was associated with a 17% lower AUC_{0-inf} and 28% higher C_{max} compared with intact capsules.

Stable kidney and liver transplant recipients were converted from twice-daily Prograf (immediate-release formulation) to once-daily Advagraf (extended-release formulation) on a

1:1 (mg:mg) total daily dose basis to achieve appropriate tacrolimus blood concentrations. The ratio and CI of the AUC after conversion from Prograf to Advagraf are shown in the table below (Table 9).

Table 9: Relative Biopharmaceutics (AUC₀₋₂₄) at Steady State in Stable Transplant Recipients Converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation)

	N	Advagraf/Prograf	90% CI
Adult Kidney Transplant Recipients	66	95.0%	90.7%, 99.4%
Adult Liver Transplant Recipients	62	88.8%	85.4%, 92.3%
Pediatric Liver Transplant Recipients	18	100.9%	90.8%, 112.1%

CI: confidence interval. Least square mean parameters were generated from ANOVA. The ratio of least square mean AUC₀₋₂₄ and 90% confidence intervals consist of natural log-transformed values (expressed as a percent) transformed back to linear scale. For all adult studies, data represent a comparison of two steady state profiles for each drug.

There was a strong correlation between trough (C_{min}) and exposure (AUC₀₋₂₄) after Advagraf administration in *de novo* kidney ($r=0.83$) and *de novo* liver ($r=0.92$) transplant recipients as well as postconversion to Advagraf in kidney ($r=0.86$) and liver ($r=0.90$) transplant recipients.

Food Effects: The presence of food affects the absorption of tacrolimus; the rate and extent of absorption is greatest under fasted conditions. In 24 healthy volunteers, administration of Advagraf immediately following a high fat meal (150 protein calories, 250 carbohydrate calories, and 500 to 600 fat calories) reduced C_{max} , AUC_{0-t}, and AUC_{0-inf} by approximately 25% compared with fasting values. Food delayed the median T_{max} from 2 hours in the fasted state to 4 hours in the fed state; however the terminal half-life remained 36 hours regardless of dosing conditions.

In 24 healthy volunteers, the time of the meal affected tacrolimus bioavailability. When Advagraf was administered immediately after consumption of a high-fat breakfast, tacrolimus AUC_{0-inf} was decreased approximately 25% relative to the fasted state. When Advagraf was administered 1.5 hours after consumption of a high-fat breakfast, tacrolimus exposure was decreased approximately 35%. Administration of Advagraf 1 hour prior to a high-fat breakfast reduced tacrolimus exposure by 10%.

In 23 healthy volunteers, a diurnal effect on the absorption of tacrolimus was observed. Evening dosing of Advagraf reduced AUC_{0-inf} by 35% relative to morning dosing.

Distribution

The apparent volume of distribution (based on whole blood concentrations) of tacrolimus is approximately 1.91, 1.41 and 0.85 L/kg in healthy volunteers, kidney and liver transplant patients, respectively (Table 10).

Table 10: Distribution in healthy volunteers and kidney and liver transplant patients

Parameter	Volunteers (n=8)	Kidney Transplant Patients (n=26)	Liver Transplant Patients (n=17)
Mean IV Dose	0.025 mg/kg/4 hr	0.02 mg/kg/4 hr	0.05 mg/kg/12 hr
V (L/kg)	1.91 ± 0.31	1.41 ± 0.66	0.85 ± 0.3
Cl (L/hr/kg)	0.040 ± 0.009	0.083 ± 0.050	0.053 ± 0.017

The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50 ng/mL. Tacrolimus is bound to proteins, mainly albumin and alpha-1-acid glycoprotein, and has a high level of association with erythrocytes. The distribution of tacrolimus between whole blood and plasma depends on several factors, such as hematocrit, temperature at the time of plasma separation, drug concentration, and plasma protein concentration. In a U.S. study in which tacrolimus was administered as Prograf (immediate-release formulation), the ratio of whole blood concentration to plasma concentration averaged 35 (range 12 to 67).

Metabolism

Tacrolimus is extensively metabolized in the liver by the mixed-function oxidase systems, primarily the cytochrome P-450-3A4 (CYP3A4) and the cytochrome P450-3A5 (CYP3A5) enzyme systems. A metabolic pathway leading to the formation of 8 possible metabolites has been proposed. Demethylation and hydroxylation were identified as the primary mechanisms of biotransformation *in vitro*. The major metabolite identified in incubations with human liver microsomes is 13-demethyl tacrolimus. In *in vitro* studies, a 31-demethyl metabolite has been reported to have the same activity as tacrolimus; the 13-demethyl, 15-demethyl and 15- and 31- double-demethylated metabolites were shown to retain an activity of less than 10%.

Elimination

The mean clearance following IV administration of tacrolimus is 0.040, 0.083 and 0.053 L/hr/kg in healthy volunteers, adult kidney transplant patients and adult liver transplant patients respectively. In man, less than 1% of the dose administered is excreted unchanged in urine.

Human Studies

The pharmacokinetic profile of tacrolimus as Prograf (immediate-release formulation) after intravenous or oral administration is well defined. Tacrolimus as Prograf (immediate-release formulation) requires twice-a-day dosing. Tacrolimus extended-release formulation (Advagraf) was developed as a once-a-day morning dosing formulation. Evidence to date with tacrolimus as Prograf (immediate-release formulation) indicates that the total exposure over a dosing interval as measured by AUC or trough whole blood concentration is most important for determining the risk of acute rejection after organ transplantation.

In contrast, tacrolimus whole blood peak concentrations (C_{max}) following administration as Prograf (immediate-release formulation) do not appear to be predictive of either the risk of biopsy-confirmed acute rejection or the likelihood of an adverse event. No statistically significant relationship between tacrolimus whole blood C_{max} and adverse events or biopsy-confirmed acute rejection was found using a Cox regression analysis (with time to the first event as the dependent variable and maximum value of the peak concentration as a covariate) of data from 181 kidney transplant recipients who received Prograf (immediate-release formulation). However, while not predictive of any individual adverse event, a higher C_{max} could potentially increase the overall safety risk.

Therefore, the target biopharmaceutic goals for the development of a once-a-day formulation of tacrolimus were to achieve AUC relative to Prograf (immediate-release formulation) within equivalence criteria and an equal or reduced C_{max} as compared with that of Prograf (immediate-release formulation). In addition, clinical development of a once-a-day formulation required a good correlation of trough concentration to AUC (similar to that obtained for Prograf [immediate-release formulation]) and the same trough target range as Prograf (immediate-release formulation), using the same therapeutic monitoring system.

The pharmacokinetic parameters of the tacrolimus extended-release formulation (Advagraf) has been studied in patients. Results indicate that the same therapeutic monitoring as used with Prograf (immediate-release formulation) can be used with tacrolimus extended-release formulation. In addition, the same trough target range as used with Prograf (immediate-release formulation) can be used with tacrolimus extended-release formulation. In conversion patients, tacrolimus exposure (AUC_{0-24}) at steady state is equivalent between Prograf (immediate-release formulation) and extended-release formulation supporting continued prophylaxis of organ rejection. Data from studies of transplant recipients indicate that once-daily administration of tacrolimus extended-release formulation results in consistently lower C_{max} values than twice-daily administration of Prograf (immediate-release formulation). In addition, pharmacokinetic profiles for tacrolimus extended-release formulation did not indicate signs of dose dumping (i.e., complete dose is more rapidly released from the dosage form) during any treatment.

Table 11: Relative Biopharmaceutics (AUC₀₋₂₄) at Steady State

Study Population	N	Advagraf (extended-release) / Prograf (immediate-release) (Ratio of Least Square Means)	90% CI
Adult Kidney	66	95.0%	90.7%, 99.4%
Adult Liver	62	88.8%	85.4%, 92.3%
Pediatric Liver	18	100.9%	90.8%, 112.1%

Patient Base: stable transplant recipients converted from Prograf (immediate-release formulation) to tacrolimus extended-release formulation (Advagraf). The least square mean parameters were generated from ANOVA. Ratio of parameter means and 90% confidence intervals consist of natural log-transformed parameters (expressed as a percent) transformed back to linear scale. For all adult studies, data represent a comparison of two steady state profiles for each drug.

CI: confidence interval.

There are no adequate and well-controlled studies in pregnant women. Tacrolimus is transferred across the placenta and infants exposed to tacrolimus *in utero* may be at a risk of prematurity, birth defects/congenital anomalies, low birth weight, and fetal distress. The use of tacrolimus during pregnancy has been associated with preterm delivery, neonatal hyperkalemia and renal dysfunction. Tacrolimus may increase hyperglycemia in pregnant women with diabetes (including gestational diabetes). Monitor maternal blood glucose levels regularly. Tacrolimus may exacerbate hypertension in pregnant women and increase pre-eclampsia. Monitor and control blood pressure. Females and males of reproductive potential should consider the use of appropriate contraception prior to starting treatment with tacrolimus. Advagraf should be used during pregnancy only if the potential benefit to the mother justifies potential risk to the fetus.

In experience reported by the University of Pittsburgh, eleven female transplant patients maintained on tacrolimus therapy throughout pregnancy delivered twelve babies, with one patient conceiving twice. These patients received tacrolimus from week one to 20 months prior to conception. Ten of the pregnancies were successful, four with C-sections. The neonates showed no growth retardation or congenital anomalies. Hyperkalemia was observed in the majority of babies, but resolved within 24-48 hours without adverse effects. Two babies (both premature 22 and 24 weeks) died shortly after birth. One pregnancy was complicated by diabetes, hypertension and proteinuria, the other by CMV infection requiring ganciclovir therapy. Additional information includes a report of one newborn who had temporary anuria associated with high cord blood tacrolimus concentration, however, renal function was normal within one week. Another reference reports on the successful pregnancy (normal healthy male) in a 28 year-old female with bolus steroids and increased doses of tacrolimus for liver graft

rejection. In this case, the cord blood plasma concentration was approximately one half that noted in maternal plasma.

Special Populations and Conditions

- **Pediatrics**

Experience with tacrolimus in pediatric kidney transplant patients is limited.

- **Geriatrics**

The pharmacokinetics of tacrolimus has not been established in the geriatric population.

- **Sex**

Data from kidney transplant recipients converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) in a phase II, open-label study showed equivalence in exposure for both male and female patients; the ratio of least square means (Advagraf:Prograf) for AUC_{0-24} at steady state was 92.0% [90% CI: 86.1%, 98.3%] for females (n=24) and 96.7% [90% CI: 90.9%, 102.9%] for males (n=42).

Similar data from a phase II, open-label study in liver transplant recipients converted from Prograf to Advagraf showed equivalence in exposure for both male and female patients; the ratio of least square means (Advagraf:Prograf) for AUC_{24} at steady state was 89.2% [90% CI: 82.7%, 96.1%] for females (n=26) and 88.5% [90% CI: 84.9%, 92.3%] for males (n=36).

- **Ethnic Origin**

The data from Advagraf administration in *de novo* kidney transplant patients indicate that Black patients required a higher dose to attain comparable trough concentrations compared to White patients.

Black kidney transplant recipients (n=12) were converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation) on a 1:1 (mg:mg) total daily dose basis. The ratio of least square means (Advagraf:Prograf) for AUC_{0-24} at steady state was 109.8% [90% CI: 99.0%, 121.7%] for Black patients. Intra-subject variability in exposure for Black patients was reduced with Advagraf compared with Prograf.

- **Hepatic Insufficiency**

The pharmacokinetics of tacrolimus administered as Prograf (immediate-release formulation) were determined in six subjects with mild hepatic dysfunction (mean Pugh score: 6.2) following single IV and oral administrations. The pharmacokinetic parameters obtained were as follows:

Table 12: Tacrolimus (Immediate-Release Formulation) Pharmacokinetics in Patients with Mild Hepatic Impairment

Parameter (N = 6)	Dose and Route	
	7.7 mg P.O.	1.3 mg IV
Age Range (yrs)	52-63	
Absolute Bioavailability (%)	22.3 ± 11.4	-
C _{max} (ng/mL)	48.2 ± 17.9	-
T _{max} (hr)	1.5 ± 0.6	-
AUC ₀₋₇₂ (ng•hr/mL)	488 ± 320	367 ± 107
V (L/kg)	3.7 ± 4.7*	3.1 ± 1.6
Cl (L/hr/kg)	0.034 ± 0.019*	0.042 ± 0.020
t _{1/2} (hr)	66.1 ± 44.8	60.6 ± 43.8

*Corrected for bioavailability.

The disposition of tacrolimus in patients with mild hepatic dysfunction was not substantially different from that in normal volunteers (see previous tables). In general, tacrolimus elimination half-life was longer and volume of distribution larger in patients with mild hepatic dysfunction compared to normal volunteers. The clearance in both populations was similar and since tacrolimus is extensively metabolized at multiple sites, patients with mild hepatic dysfunction may not require lower maintenance doses of tacrolimus than patients with normal hepatic function.

Tacrolimus pharmacokinetics were also studied in 6 subjects with severe hepatic dysfunction (mean Pugh score > 10) administered Prograf (immediate-release formulation). The mean clearance was substantially lower in patients with severe hepatic dysfunction, irrespective of the route of administration.

Table 13: Tacrolimus (Immediate-Release Formulation) Pharmacokinetics in Patients with Severe Hepatic Impairment

Route, N	Dose	AUC ng•hr/mL (0-t)	T _{1/2} (hr)	V (L/kg)	Cl (L/hr/kg)
IV, n=6	0.02 mg/kg/4 hr IV (n=2)	762 (t=120 hr)	198 ± 158	-	-
	0.01 mg/kg/8 hr IV (n=4)	289 ± 117 (t=144 hr)	Range: 81- 436	3.9 ± 1.0	0.017 ± 0.013

Route, N	Dose	AUC ng•hr/mL (0-t)	T _{1/2} (hr)	V (L/kg)	Cl (L/hr/kg)
PO, n=5†	8 mg PO (n=1)	658 (t=120 hr)	119 ± 35 Range: 85-178	3.1 ± 3.4	0.016 ± 0.011
	5 mg PO (n=4)	533 ± 156 (t=144 hr)			
	4 mg PO (n=1)	-			

† 1 patient did not receive the PO dose.

- **Renal Insufficiency**

The pharmacokinetics of tacrolimus following a single IV administration of Prograf were determined in 12 subjects (7 not on dialysis and 5 on dialysis). The pharmacokinetic parameters obtained are presented in the table below:

Table 14: Tacrolimus Pharmacokinetics in Patients with Renal Insufficiency

Serum Creatinine (mg/dL)	3.9 ± 1.6 (not on dialysis) 12.0 ± 2.4 (on dialysis)
Age range (yrs)	25-65
Route	IV
Dose (mg)	1.17 ± 0.28
AUC ₀₋₆₀ (ng•hr/mL)	393 ± 123
AUC _{0-inf} (ng•hr/mL)	499 ± 155
V (L/kg)	1.07 ± 0.20
Cl (L/hr/kg)	0.038 ± 0.014
t _{1/2} (hr)	26.3 ± 9.2

The disposition of tacrolimus in patients with renal dysfunction was not different from that in normal volunteers (see previous tables). The clearance was similar whereas volume of distribution was smaller and the mean terminal elimination half-life shorter than that of normal volunteers.

Diabetes: Stable kidney transplant recipients who had diabetes or new onset diabetes after transplant (NODAT) and were converted to Advagraf had ratios of least square means (Advagraf:Prograf) for AUC₀₋₂₄ of 92.0% [90% CI: 84.8%, 99.7%] in kidney transplant recipients (n=13).

11 STORAGE, STABILITY AND DISPOSAL

Store and dispense at controlled room temperature, 15°C – 30°C.

12 SPECIAL HANDLING INSTRUCTIONS

Based on immunosuppressive effects of tacrolimus, inhalation or direct contact with skin or mucous membranes of powder contained in tacrolimus products should be avoided. If such contact occurs, wash the skin and eyes.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: tacrolimus

Chemical name: [3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, monohydrate.

Molecular formula and molecular mass: $C_{44}H_{69}NO_{12} \cdot H_2O$ and 822.03

Structural formula:



Physicochemical properties: Tacrolimus appears as white crystals or crystalline powder. It is practically insoluble in water, freely soluble in ethanol, and very soluble in methanol and chloroform.

Melting Point: 124.9 - 126.8°C by thermal analysis

Partition Coefficient: > 1000 (in n-octanol/water)

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Kidney Transplantation

Table 15: Summary of patient demographics for clinical trials in kidney transplantation

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
KIDNEY – De novo transplant						
02-0-158	Phase III randomized, open-label, multicentre, comparative	Advagraf (extended-release): initial dose 0.15 mg - 0.2 mg/kg/day, orally, once daily morning, 1 year.*	214	47.84 ± 12.995 (17-77)	M=138 F=76	160/41/5/8
		Prograf (immediate-release): initial dose 0.075 mg - 0.1 mg/kg orally, twice daily, 1 year.*	212	48.62 ± 12.855 (19-74)	M=136 F=76	152/51/5/4
		Neoral: initial dose 4 -5 mg/kg, orally, twice daily, 1 year.*	212	47.63 ± 12.953 (17-77)	M=130 F=82	163/36/8/5
FG-506E-12-01	Phase II, open-label, randomized, multi-center, comparative trial	Advagraf (extended-release): Initial dose 0.2 mg/kg orally, once daily morning‡. Study duration 6 weeks.	60	44.0 (19-66)	M=34 F=26	58/0/0/2
		Prograf (immediate-release): Initial dose 0.2 mg/kg orally, twice daily‡. Study duration 6 weeks.	59	43.6 (21-65)	M=44 F=15	59/0/0/0

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
KIDNEY – Transplant Recipients Converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation)						
02-0-131	Phase II, open-label, multicenter, safety, PK conversion (1:1) study	Individualized oral dose (tacrolimus trough levels 5-20 ng/mL). The Prograf (immediate-release) twice daily dose is given for 1 week followed by Advagraf (extended-release) once daily dose for 4 weeks.	68	46.7 ± 12.57 (22-71)	M=42 F=26	54/12/1/1
FG-506E-12-02 (Alloway, 2005) ¹	Phase II, open-label, multi-centre, single-sequence, four period crossover replicate design, comparative PK study.	Individualized oral dose (tacrolimus trough levels 5-15 ng/mL). Prograf (immediate-release) twice daily or Advagraf (extended-release) once daily for 14 days for each of 4 treatment periods.	69	44.8 (20-65)	M=49 F=20	52/1/8/8

W=White, B=Black, A=Asian, O=other (includes East Indian, Pacific Islander, Native Hawaiian, Filipino, Brazilian Indian).

*Target concentration range for tacrolimus (Advagraf [extended-release formulation] and Prograf [immediate-release formulation]) was 7 –16 ng/mL for days 0-90 and 5 to 15 ng/mL thereafter.

‡Target trough concentration 10-20 ng/mL (day 1- 14) and 5 -15 ng/mL (day 15-week 6).

Liver Transplantation

Table 16: Summary of patient demographics for clinical trials in liver transplantation

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
LIVER – De novo transplant						
FG-506E-11-03 (Trunecka 2010) ¹³	Phase III randomized, double-blind (24 weeks, open label (12 months), multicentre, comparative trial, with PK substudy	Advagraf (extended-release): initial dose 0.2 mg/kg/day + corticosteroids, orally, once daily morning. Study Duration: 14 days PK and 1 year Efficacy and Safety.	237	52.7 ± 9.1 (24-70)	M=161 F=76	233/1/0/3
		Prograf (immediate-release): initial dose 0.05 mg/kg + corticosteroids, orally, twice daily. Study Duration: 14 days PK and 1 year Efficacy and Safety.	234	52.8 ± 9.5 (19-72)	M=170 F=64	225/1/2/6
FG-506E-11-01	Phase II, open-label, randomized, multi-centre, comparative trial	Advagraf (extended-release): Initial dose 0.1-0.15 mg/kg + corticosteroids, orally, once daily morning‡. Study duration 6 weeks.	67	49.4 ± 10.2 (24-65)	M=49 F=18	65/1/0/1

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
		Prograf (immediate-release): Initial dose 0.05-0.075 mg/kg + corticosteroids, orally, twice daily. Study duration 6 weeks.	62	52.4±9.1 (27-68)	M=45 F=17	61/0/1/0

Table 17: LIVER– Transplant Recipients Converted from Prograf (immediate-release formulation) to Advagraf (extended-release formulation)

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
02-0-152 (Florman, 2007) ⁴ and (Florman, 2005) ⁵	Phase II, open-label, multicentre, 4 period crossover, Pharmacokinetic, safety study	Individualized oral dose (tacrolimus trough levels 10-20 ng/mL). The Prograf (immediate-release) twice daily dose is given on day 1 day 14 and on day 29 and 42. They converted to Advagraf (extended-release) on day 15, 28 and day 43 and day 56. Some patients were followed up for 5 years period.	70	49.6 ± 9.08 (24-68)	M=40 F=30	65/5/0/1

Study #	Trial design	Dosage, route of administration and duration	Number of study subjects	Mean age (Range)	Gender	Race (W/B/A/O)
02-0-160 (Heffron, 2007) ⁶	Phase II, open-label, multi-centre, two parallel, conversion in stable pediatric liver transplant recipients	Individualized oral dose (tacrolimus trough levels 5-15 ng/mL). Prograf (immediate-release) twice daily or Advagraf (extended-release) once daily for 7 days followed by Long term safety study.	19	9 (5-13)	M=6 F=13	11/8/8/0

W=White, B=Black, A=Asian, O=other.

14.2 Study Results

Kidney Transplantation

Kidney Transplant Recipients

The efficacy and safety of Advagraf[®] (extended-release formulation) + mycophenolate mofetil (MMF) and corticosteroids (S) (n=214) was compared with that of Prograf[®] (immediate-release formulation) + MMF + S (n=212) and Neoral[®] + MMF + S (n=212) in a phase III, randomized (1:1:1), multi-center, open-label, comparative, non-inferiority study in *de novo* kidney transplant recipients. Study drugs were administered as initial oral doses as follows: Prograf (immediate-release formulation) 0.075-0.10 mg/kg twice daily, Advagraf (extended-release formulation) 0.15-0.20 mg/kg once daily AM; Neoral 4-5 mg/kg twice daily. MMF was administered according to package insert (CellCept[®]). Dosing of these immunosuppressants was adjusted based on clinical evidence of efficacy, safety and/or whole blood trough concentrations. Patients received two 20 mg IV doses of basiliximab induction therapy. Efficacy failure was a composite endpoint comprising any patient who died, had graft failure (return to dialysis >30 days or retransplant), had a biopsy confirmed acute rejection, or was lost to follow-up. Efficacy failure rates at 1 year were similar among treatment groups (Table 16, Table 17, Table 18, and Table 19).

Table 18: Efficacy Failure in *De Novo* Kidney Transplant Recipients at 1 Year Post-transplant

	Advagraf (extended-release)/MMF (n=214)	Prograf (immediate-release)/MMF (n=212)	Neoral/MMF (n=212)
Efficacy Failure	14.0%	15.1%	17.0%

	Advagraf (extended-release)/MMF (n=214)	Prograf (immediate-release)/MMF (n=212)	Neoral/MMF (n=212)
Treatment Difference	-3.0%	-1.9%	
95.2% CI	-9.9%, 4.0%	-8.9%, 5.2%	

CI: confidence interval. Treatment differences are relative to Neoral treatment group (Advagraf minus Neoral; Prograf minus Neoral).

Table 19: Patient and Graft Survival in *De Novo* Kidney Transplant Recipients at 1 Year Post-transplant

	Advagraf (extended-release)/MMF (n=214)	Prograf (immediate-release)/MMF (n=212)	Neoral/MMF (n=212)
Patient Survival	98.6%	95.7%	97.6%
Kaplan-Meier Estimate Difference	1.0%	-1.9%	-
95% CI	-1.6%, 3.6%	-5.3%, 1.5%	
Graft Survival	96.7%	92.9%	95.7%
Kaplan-Meier Estimate Difference	1.0%	-2.9%	-
95% CI	-2.7%, 4.6%	-7.3%, 1.6%	

CI: confidence interval. Kaplan-Meier estimate differences are relative to Neoral treatment group (Advagraf minus Neoral; Prograf minus Neoral). Data censored at time of last follow-up.

Table 20: Renal Function in *De Novo* Kidney Transplant Recipients at 6 and 12 Months Post-transplant

	Advagraf (extended-release)/MMF (n=214)	Prograf (immediate-release)/MMF (n=212)	Neoral/MMF (n=212)	p-values	
				Advagraf (extended-release) vs. Neoral	Prograf (immediate-release) vs. Neoral
<i>Mean Serum Creatinine Levels (mg/dL):</i>					
6 Months	1.46±0.55	1.42±0.43	1.51±0.50	0.238	0.015
12 Months	1.39±0.44	1.42±0.56	1.48±0.51	0.047	0.057
<i>Mean Creatinine Clearance Levels (mL/min):</i>					
6 Months	56.7±18.24	56.8±17.25	53.6±15.92	0.036	0.015
12 Months	58.7±18.26	57.7±18.81	54.6±17.60	0.008	0.013

Table 21: Additional Efficacy Data in *De Novo* Kidney Transplant Recipients at 1 Year Post-transplant

	Advagraf (extended-release)/ MMF (n=214)	Prograf (immediate-release)/ MMF (n=212)	Neoral/ MMF (n=212)	p-values	
				Advagraf (extended-release) vs. Neoral	Prograf (immediate-release) vs. Neoral
Treatment Failure	14.5%	15.6%	28.8%	<0.001	0.001
Cross Over Due to Treatment Failure	4.7%	2.8%	18.4%	<0.001	<0.001
Patient Discontinuations					
Adverse Events	8.9%	10.8%	17.5%	0.010	0.069
Non-compliance	0.9%	1.9%	2.4%	0.283	1.000
Rejection	0.5%	0	7.5%	<0.001	<0.001

Treatment failure is defined as discontinuation of randomized study drug for any reason.

Transplant Recipients Converted from Prograf to Advagraf

Data from phase II, randomized, comparative, open-label studies showed that kidney transplant recipients were safely converted from Prograf (twice daily) to Advagraf (once daily) on a 1:1 (mg:mg) total daily dose basis to achieve appropriate tacrolimus whole blood concentrations. The majority of patients in these studies did not require Advagraf (extended-release formulation) dosing adjustments in the early conversion period (Table 18).

Table 22: Patient and Graft Survival in Stable Transplant Recipients 1 or 2 Years After Conversion from Prograf (Immediate-Release Formulation) to Advagraf (Extended-Release Formulation)

	Patient Survival	Graft Survival
US Adult Kidney Study (2 Years)	100%	98.5%
EU Adult Kidney Study (1 Year)	97.0%	97.0%

Kaplan-Meier estimates.

There were no graft losses due to rejection in the kidney conversion studies.

Liver Transplantation

Liver Transplant Recipients

In Study FG-506E-11-03, the primary efficacy endpoint was the event rate of patients with BPAR within the first 24 weeks (based on local biopsy assessment) and at 12 months. Efficacy failure was also assessed in Study FG-506E-11-03 as well as patient and graft survival.

For the primary efficacy endpoint of BPAR at 24 weeks, the local BPAR event rates (Kaplan-Meier analysis) were 32.6% for the Advagraf group and 29.3% for the Prograf group. The difference in the event rates (Advagraf minus Prograf) was 3.3% with 95% Confidence Interval [CI] of -5.7% to 12.3% [Table 19]. The CI for the difference between the treatment arms was within the predefined noninferiority margin of 15%, demonstrating noninferiority of Advagraf vs Prograf.

Overall, the frequency of BPAR events and event-rates of BPAR episodes at 12 months were similar to the 24-week results and were similar for both treatment groups. Similarly, the difference in the event rates (Advagraf minus Prograf) was 3.3% with 95% CI of -5.9% to 12.5% at 12 months.

Table 23: Event Rate of Patients with Local BPAR within the First 24 Weeks and 12 Months in Study FG-506E-11-03

	Advagraf (extended-release)/corticosteroid (n=237)	Prograf (immediate-release)/corticosteroid (n=234)
Event rate for BPAR (FAS) – 24 weeks	32.6%	29.3%
Treatment Difference [†]	3.3%	
95% CI	-5.7%, 12.3%	
P value [‡]	0.354	
Event rate for BPAR (FAS) – 12 months	33.8%	30.5%
Treatment Difference [†]	3.3%	
95% CI	-5.9%, 12.5%	
P value [‡]	0.356	
BPAR frequency (12 months)	29.5%	26.9%
Treatment difference [†]	2.6%	
95% CI	-5.5%, 10.7%	
P value [‡]	0.490	

BPAR: biopsy-proven acute rejection; FAS: Full Analysis Set.

[†] Rate of Advagraf arm minus the rate of the Prograf arm.

[‡] Wilcoxon-Gehan test for a difference between treatments over 24 weeks.

In the phase III study, the Event Rate of patients with Local BPAR at 12 months were similar

between Advagraf and Prograf. The difference in the event rates (Advagraf minus Prograf) was 2.6% with 90% CI of -5.5% to 10.7%.

The Kaplan-Meier estimated patient survival rates were similar at both 24 weeks post-transplant (Advagraf: 92.2%; Prograf: 93.5%) and at 12 months post-transplant (Advagraf: 89.2%; Prograf: 90.8%) [Table 21]. The Kaplan-Meier estimated patient survival rates were also similar at both 24 weeks and 12 months post-transplantation.

The Kaplan-Meier estimated graft survival rates were similar at both 24 weeks post-transplant (Advagraf: 88.8%; Prograf: 89.1%) and at 12 months post-transplant (Advagraf: 85.3%; Prograf: 85.6%). The Kaplan-Meier estimated graft survival rates were also similar at both 24 weeks and 12 months post-transplant.

Table 24: Kaplan-Meier Estimates of Patient Survival and Graft Survival in Study FG-506E-11-03

Parameter	Advagraf (n = 237)	Prograf (n = 234)
Patient survival		
24 weeks	92.2%	93.5%
12 months	89.2%	90.8%
Graft survival		
24 weeks	88.8%	89.1%
12 months	85.3%	85.6%

In a post-hoc analysis of study FG-506E-11-03, *de novo* liver transplant study (n=571), a higher mortality rate at 12 months was observed in female patients treated with Advagraf (14/76, 18.4%) than in female patients treated with Prograf (5/64, 7.8%) or male patients treated with Advagraf (11/161, 6.8%).

Transplant Recipients Converted from Prograf to Advagraf

Data from phase II, randomized, comparative, open-label studies showed that adult and pediatric liver transplant recipients were safely converted from Prograf (twice daily) to Advagraf (once daily) on a 1:1 (mg:mg) total daily dose basis to achieve appropriate tacrolimus whole blood concentrations. The majority of patients in these studies did not require Advagraf (extended-release formulation) dosing adjustments in the early conversion period. The Kaplan-Meier estimates of both patient and graft survival at 4 years for study 02-0-160 were 94.4% and 94.7% and 93.0% for patient and graft survival after 5 years in study 02-0152 (Table 22).

Table 25: Patient and Graft Survival in Stable Transplant Recipients 4 or 5 Years After Conversion from Prograf (Immediate-Release Formulation) to Advagraf (Extended-Release Formulation)

	Patient Survival	Graft Survival
02-0-160 Pediatric Liver Study (4 Years)	94.4%	94.4%
02-0-152 Adult Liver Study (5 Years)	94.7%	93.0%

Eighteen stable pediatric (5 to 13 years of age) liver transplant recipients were converted from Prograf to Advagraf on a 1:1 (mg:mg) total daily dose basis. Dose errors were the main reason for dose adjustments after the conversion. Sixteen patients were enrolled in the 5 year extension study. There were no episodes of acute rejection or graft failure, no deaths and no patient discontinued the study due to an adverse event through 2 year postconversion. Significant Advagraf dose increases in this clinical trial were observed, from 4.0 mg mean daily dose at beginning of the study to 8.0 mg mean daily dose by the end of the 4 year period of study.

15 MICROBIOLOGY

Not Applicable.

16 NON-CLINICAL TOXICOLOGY

The tacrolimus toxicology profile is well defined and was established as part of the development program for Prograf (immediate-release formulation). No additional toxicology studies were performed as part of the development for the tacrolimus extended-release formulation (Advagraf). Toxicology data summarized from the Prograf Product Monograph is presented below.

Animal Studies

The primary mechanism of rejection following transplantation involves activation of T-lymphocytes and the subsequent formation of factors such as interleukin-2 (IL-2). Tacrolimus inhibits the activation of T-lymphocytes in both animals and humans, especially the activation that is calcium-dependent. The minimum inhibitory tissue culture level of tacrolimus that prevents antigen stimulation of T-lymphocytes is 0.1 nM - 0.3 nM. Tacrolimus interferes with the formation of active transcription factor NF-AT (nuclear factor of activated T-cells) and inhibits the formation of lymphokines such as IL-2, IL-3, IL-4, and interferon- γ . The net result is immunosuppression.

Safety pharmacology studies in mice, rats, dogs, cats, and rabbits and with various tissues *in vitro* have been conducted as part of the Prograf (immediate-release formulation) development program for liver and kidney transplantation.

At intravenous doses of 0.32 to 3.2 mg/kg, and at oral doses of 3.2 to 32 mg/kg, tacrolimus showed little effect on general activity and the central nervous system; little or no effect on somatic and autonomic nervous systems and smooth muscle.

Most of the effects shown by IV tacrolimus in dogs and cats were also shown by the tacrolimus-placebo IV formulation. Intravenous tacrolimus at ≥ 0.1 mg/kg increased the respiration rate in dogs only; blood pressure was decreased by IV tacrolimus at ≥ 0.1 mg/kg in dogs, to a lesser extent at 3.2 mg/kg in cats, and by PO tacrolimus at 32 mg/kg in rats; heart rate was decreased by IV tacrolimus at ≥ 0.1 mg/kg in dogs, at ≥ 0.32 mg/kg in cats, at 3.2 mg/kg in rats, and by PO tacrolimus at 10 and 32 mg/kg in rats; blood flow in femoral artery of dogs was decreased by IV tacrolimus at ≥ 0.1 mg/kg; carotid artery blood flow was increased at 3.2 mg/kg IV in cats.

Intravenous tacrolimus at ≥ 1.0 mg/kg increased pilocarpine-induced salivary secretion in rabbits and decreased gastric fluid secretion in rats; and, at 3.2 mg/kg, increased accumulation of intestinal fluid and slightly inhibited gastrointestinal transit rate in rats. Intravenous tacrolimus did not affect bile secretion nor produce irritation to gastric mucosa in rats. Gastrointestinal transit rate and accumulation of intestinal fluid in rats were not affected by PO tacrolimus. Bleeding time in mice and prothrombin time and activated partial thromboplastin time in rats were not affected by IV or PO tacrolimus. Tacrolimus did not affect ADP- or collagen-induced aggregation of rabbit platelets, or produce hemolysis in rabbit blood. Oral tacrolimus at 32 mg/kg slightly increased urine volume and Na^+ excretion, but not excretion of K^+ , Cl^- , or uric acid, in rats; IV tacrolimus at 3.2 mg/kg had no effect. Oral tacrolimus had no effect on carrageenin-induced paw edema in rats.

When ^{14}C -tacrolimus was dosed orally to pregnant or lactating rats, trace amounts of tacrolimus were found in fetal liver and in breast milk, respectively.

When ^{14}C -tacrolimus was administered to rats, either intravenously or orally, total recovery of radioactivity in urine and feces was over 95%. Trace amounts of unchanged tacrolimus, as well as small amounts of numerous metabolites, were detected in urine, feces, and bile, indicating that the drug is extensively metabolized. *In vitro* studies identified the main metabolite as 13-demethylated-tacrolimus in animals and humans.

Tacrolimus as Prograf (immediate-release formulation) significantly prolonged host survival and/or graft viability in animal transplant models involving the liver, kidney, heart, small bowel, lung, pancreas, pancreatic islet, bone marrow, skin, limb, cornea, and trachea. A dose range of 0.1 to 1 mg/kg/day PO or IM was used in most studies in various dosing regimens: (pre- and post-surgery, short- and long-term administration).

To assess the relationship of peak concentration versus area under the curve (AUC) to efficacy, a study was conducted to evaluate the effect of tacrolimus in preventing skin allograft rejection when administered as a bolus (comparable with immediate-release) or when continuously infused (sustained-release profile somewhat representative of the extended-release formulation). In this study, ear skin grafts from Fisher rats were transplanted to the thorax of MCH-incompatible recipients (WKAH rats). Tacrolimus (0.01 mg/kg, 0.1 mg/kg, 1.0 mg/kg) or placebo was administered to four groups of male rats (7 or 8/group) by daily bolus intramuscular injections (IM) or continuous intravenous infusion (IV) for 14 days with mini-osmotic pumps starting on the day of graft placement. The median survival times of the allografts were counted in days after transplantation (Table 26).

Table 26: Effect of Tacrolimus (FK506) on Allograft Skin Survival in Rats

	IM Dose		IV Dose	
	n	MST (days)	n	MST (days)
Control (placebo)	7	5	7	6
FK506 0.01 mg/kg	7	6	7	7
FK506 0.1 mg/kg	8	10	8	10*
FK506 1.0 mg/kg	8	20**	8	22**

*p<0.05;

**p<0.01 versus each control;

IM: Intramuscular injection;

IV: Intravenous infusion;

MST: Median survival time in days after transplantation.

At each dose tested, there were no significant differences in median skin allograft survival times between rats administered tacrolimus by intramuscular bolus injections and those receiving continuous intravenous infusion, supporting the concept that total exposure (i.e., AUC) is the critical component for the efficacy of an extended-release formulation.

Acute Toxicology

Table 27: Acute Toxicology Studies of Tacrolimus in Rats and Baboon

Species	No./ Group (M/F)	Route	Dose Range (mg/kg)	Overt Signs of Toxicology	LD ₅₀ (mg/kg)
Rat, Sprague-Dawley	5/5	Gavage	32-320	Tremor, ptosis, salivation, hyperreactivity, decreased spontaneous motility	134 (M) 194 (F)
	5/5	IV	10-100	Bloody urine, prone position, ptosis, hyper-reactivity, salivation, decreased motility	57.0 (M) 23.6 (F)

Species	No./ Group (M/F)	Route	Dose Range (mg/kg)	Overt Signs of Toxicology	LD ₅₀ (mg/kg)
Rat, Sprague-Dawley (21 days old)	5/5	Gavage	10-320	Hyperreactivity, salivation, decreased motility	70 (M) 32-100 (F)
Baboon	1/1	Gavage	5-250	Huddled posture, emesis	ND*
	1/1	IV	2-50	Debility and exhaustion: 1 of 2	ND*

*Not determined.

Repeat Dose Toxicity

Table 28: Overview of Repeated Dose Toxicity Studies of Tacrolimus

Species	Strain	No. / Group	Route	Dose (mg/kg/day)	Duration (Weeks)	NOAEL (mg/kg/day)
Rat	Crl:CD(SD)BR	20/sex	Gavage	0, 0.15, 0.5, 1.5	52	0.15
	Crl:CD(SD)BR	12/sex	Gavage	0, 0.32, 1, 3.2	13	1
	Jcl:SD†	12/sex	Gavage	0, 0.32, 1, 3.2	4	0.32
	Crl:SC(SD)BR	12/sex	IV	0, 0.032, 0.1, 0.32, 1	4	0.032
Baboon	<i>Papio spp.</i>	4/sex	Gavage	0, 1, 3.2, 10	52	1
		3/sex	Gavage	0, 18, 36	13	-
		3/sex	Gavage	0, 1, 3, 6, 9	13	1
		3/sex	IV	0, 0.5, 1, 2	4	-

NOAEL (no observable adverse effect level (no observable toxic effect)).

† Immature rats.

Both rats and baboons showed a similar toxicologic profile following oral or intravenous administration of tacrolimus. Toxicity following intravenous administration was evident at lower doses than after oral administration for both rats and baboons. Toxicity was seen at lower doses in rats than in baboons. The primary target organs of toxicity were the kidney, pancreatic islets of Langerhans and exocrine pancreas, spleen, thymus, gastrointestinal tract, and lymph nodes. In addition, decreases in erythrocyte parameters were seen. Effects such as atrophy of the spleen, lymph nodes, and thymus may be a reflection of the immunosuppressant actions of tacrolimus. In rats, chronic oral administration of tacrolimus at high doses resulted in changes in sex organs, and glaucoma/eye changes.

Genotoxicity

No evidence of genotoxicity was seen in bacterial (*Salmonella* and *E. coli*) or in mammalian (Chinese hamster lung-derived cells) *in vitro* assays of mutagenicity. Tacrolimus did not cause

unscheduled DNA synthesis in rodent hepatocytes in either the *in vitro* CHO/HGRPT assay of mutagenicity, or *in vivo* clastogenicity assays performed in mice.

Carcinogenicity

Dietary carcinogenicity studies were carried out in rats (104-week) and mice (80-week). In the rat studies, no increased incidence of tumors was observed compared to concurrent controls, and all tumor incidence was within the range found in historical control groups. Similarly in the mouse study, tacrolimus was not associated with an increased incidence nor was there a dose related incidence of tumors compared to control animals.

Reproductive and Developmental Toxicity

The reproductive toxicity of tacrolimus was evaluated in Segment 1 (rats), Segment 2 (rats and rabbits) and Segment 3 (rats) studies. The results of these studies are summarized below in Table 29.

Table 29: Reproductive and Developmental Toxicity Studies of Orally Administered Tacrolimus

Study	Oral Dose (mg/kg/day)	Major Findings	
		Parental	F ₁ Offspring
Segment 1, Rat	0.32	No observable effect	No observable effect
	1	Incomplete delivery	No observable effect
	3.2	↓Body weight with ↓food consumption ↓Male copulatory index ↑Copulatory interval Incomplete delivery ↑Female diestrus period	Some lethality; ↓Implantation ↑Post-implantation loss ↓Embryo/offspring viability
Segment 2, Rat	0.32	No observable effect	No observable effect
	1	No observable effect	↓Fetal body weight
	3.2	Some lethality; ↓Body weight with ↓food consumption	↓Fetal body weight ↑Post-implantation loss ↓Offspring viability ↑Skeletal variations
Segment 2, Rabbit	0.1	↓Body weight	No observable effect
	0.32	↓Body weight Abortions	↑Developmental variations
	1	↓Body weight Abortions	↑Developmental variations ↑Post-implantation loss ↓Viable fetuses ↑Morphological variations

Study	Oral Dose (mg/kg/day)	Major Findings	
		Parental	F ₁ Offspring
Segment 3, Rat	0.32, 1	No observable effect	No observable effect
	3.2	↓Body weight	↓Body weight

Tacrolimus subcutaneously administered to male rats at doses of 2 or 3 mg/kg/day (1.6 to 6.4 times the clinical dose range based on body surface area) resulted in a dose-related decrease in sperm count.

Special Studies

The acute IV toxicity of known heat- and light-degradation products of tacrolimus, a tacrolimus tautomer, related compounds, and a tacrolimus metabolite was assessed in mice. The acute toxicity of these compounds was not greater than that of tacrolimus as bulk drug or as the IV formulation.

Antigenicity studies produced no antibody formation in mice, and no skin reactions, sensitization, or delayed hypersensitivity reactions.

Tacrolimus produced a reversible, dose-dependent, pancreatic islet cell toxicity in rats; there were no effects on pancreatic exocrine function.

The irritation potential of the IV formulation of tacrolimus was similar to that of 0.425% acetic acid.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **Advagraf**[®]

tacrolimus extended-release capsules

Read this carefully before you start taking **Advagraf**[®] and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Advagraf**[®].

Serious Warnings and Precautions

- Advagraf may increase your chances of getting serious infection and some kinds of cancer. These include skin cancer and lymphoma.
- Advagraf should only be prescribed by doctors with experience in the use of immunosuppressive (anti-rejection) drugs and the management of organ transplants.

What is Advagraf[®] used for?

- Advagraf is used to help prevent organ rejection.
- It is used in adults who have received a kidney or a liver transplant.
- It is used along with other medicines.
- Advagraf is the brand name for tacrolimus extended-release capsules.

How does Advagraf[®] work?

Your immune system is your body's defence system. Immunity is the way your body protects itself from infections and other foreign material. When you receive a transplant, your immune system recognizes the transplanted organ as foreign and will try to reject it. Advagraf is an anti-rejection drug that helps your body accept your transplanted organ.

What are the ingredients in Advagraf[®]?

Medicinal ingredients: Tacrolimus.

Non-medicinal ingredients: Ethylcellulose, ferric oxide, gelatin, hypromellose, lactose, magnesium stearate, sodium lauryl sulfate and titanium dioxide.

Advagraf[®] comes in the following dosage forms:

Advagraf is available in an extended-release capsule. Each capsule contains 0.5 mg, 1 mg, 3 mg or 5 mg of tacrolimus.

Do not use Advagraf[®] if:

- you are allergic to tacrolimus.
- you are allergic to any of the other ingredients in this medication or to a component of the container.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Advagraf®. Talk about any health conditions or problems you may have, including if you:

- have heart problems including congenital or acquired QT prolongation
- have or have had liver problems
- have or have had kidney problems
- have a hereditary disease of galactose intolerance, such as the Lapp lactase deficiency or glucose-galactose malabsorption, since Advagraf contains lactose
- are taking a diuretic medicine

Other warnings you should know about:

Pregnancy:

Tell your doctor if you are pregnant, think you might be pregnant, are planning to become pregnant, or father a child while taking Advagraf. Advagraf can cause development problems in an unborn baby. You should not use Advagraf if you are pregnant unless advised by your doctor. It is not known if it will harm your unborn baby. You should consider the use of a reliable method of birth control before, during your treatment and for 6 weeks after stopping your treatment with Advagraf.

Breastfeeding:

Tell your doctor if you are breastfeeding or planning to breastfeed your baby. Advagraf can pass into your breast milk. It is not known if this can harm your baby. You should not breastfeed your baby while you are taking Advagraf.

New onset diabetes:

Advagraf may cause new onset diabetes in kidney transplant patients. Your doctor may order tests to monitor your blood glucose levels.

Vaccinations and other medicines:

While you are taking Advagraf, do not get any vaccinations without your transplant team's approval. The vaccination may not work as well as it should or may result in serious side effects. Tell your doctor if you have had or are scheduled to have any vaccinations. Always check with your transplant team before starting any new medicine or supplement. You should avoid taking too much potassium while you are taking Advagraf. Talk to your doctor if you are not sure if your potassium intake is high.

Driving and using machines:

Advagraf may cause vision and nervous system problems. Wait until you know how Advagraf affects you before driving or using machines.

Skin protection:

Advagraf may increase your chances of getting some kinds of cancer including skin cancer. You must protect your skin from sunlight and UV light. Wear protective clothing and use a sunscreen with a high sun protection factor (SPF 30 or higher) while you are taking Advagraf.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Advagraf®:

- Antacids: magnesium aluminum hydrochloride
- Medicines used to treat irregular heart rhythm such as amiodarone

- Medicines used for fungal infections such as clotrimazole, fluconazole, ketoconazole, itraconazole, voriconazole
- Medicines used to treat circulation and heart problems such as diltiazem, nifedipine, verapamil
- Medicines used to treat stomach disorders such as cisapride*, metoclopramide, lansoprazole, omeprazole
- Medicines used for bacterial infections such as erythromycin, clarithromycin, troleandomycin
- Other drugs such as bromocriptine, cimetidine, chloramphenicol, cyclosporine, danazol, ethinyl estradiol, methylprednisolone, nefazodone
- Medicines used to treat HIV infection such as ritonavir, nelfinavir, and saquinavir
- Medicines used to treat HCV infection such as sofosbuvir, telaprevir and boceprevir
- Cytomegalovirus (CMV) antiviral medicines such as letermovir
- Anticonvulsant medicines used to control seizures such as carbamazepine, phenobarbital, phenytoin
- Anti-infective medicines used to treat tuberculosis such as rifampin, rifabutin, caspofungin
- Sirolimus, a medicine used to avoid rejection of the kidney transplant
- Potassium sparing diuretics such as amiloride, triamterene, or spironolactone
- St. John's wort (*Hypericum perforatum*), an herbal product used for depression
- *Schisandra sphenanthera* extracts, an herbal product with various uses
- Grapefruits or grapefruit juice
- Cannabidiol (used for the treatment of seizures and other conditions).

How to take Advagraf®:

You need to take Advagraf correctly so that it can protect your new kidney or liver. Take Advagraf exactly as your doctor and transplant team have told you to.

Your new organ needs around-the-clock protection so your body does not reject it. The success of your transplant depends a great deal upon how well you help Advagraf do its job. Here is what you need to do:

1. Take Advagraf exactly as prescribed

Your transplant team will tell you what dose to take and how to take it. It is important to take Advagraf capsules exactly as told by your transplant team. Your transplant team may adjust your dose until they find what works best for you. Never change your dose on your own. Never stop taking Advagraf even if you are feeling well. If you feel poorly on Advagraf, discuss this with your transplant team.

2. Take Advagraf once-a-day, in the morning

Try to pick a time that will be easy for you. You must take Advagraf at the same time every day. If you decide to take Advagraf at 7:00 a.m., take it at this same time every day. This will make sure you always have enough medicine in your body to give your new organ the around-the-clock protection it needs.

3. Take Advagraf the same way each day

Whether you take Advagraf with or without food, it is important to take Advagraf the same way every day. For example, if you take Advagraf with food, you should always take it with food. Do not change the way you take this medicine without telling your transplant team, since this could change the amount of protection you get from Advagraf.

4. Take your full dose of medication, every day

It is important to take your dose exactly as prescribed by your doctor. If you miss even one dose, your new kidney could lose the protection it needs against rejection by your body.

If you travel and change time zones, be sure to ask your transplant team how to adjust your dosage schedule so your new organ does not lose its protection.

5. Take the same tacrolimus medicine every time

Make sure that you receive the same tacrolimus medicine (the brand name of the medicine should always be the same) every time you collect your prescription. Advagraf should be taken once a day. If the appearance is not the same as usual, or if dosage instructions have changed, or if the brand name is different, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine. Serious side effects can occur if you do not take the exact tacrolimus medication that you are supposed to take. You need to take the exact tacrolimus medicine prescribed to you by your doctor to ensure that your organ is protected.

6. Plan ahead so that you do not run out of Advagraf

Make sure you have your prescription for Advagraf refilled and at home before you need it. Circle the date on a calendar when you need to order your refill. Allow extra time if you receive your medicines through the mail.

7. When having a blood test to measure Advagraf

On the days you are going to have a blood test to measure the amount of Advagraf in your body, your transplant team will ask you not to take your dose until after the blood sample is taken.

Avoid inhalation, or direct contact with your skin or mucous membranes with the powder inside the Advagraf capsule. If such contact occurs, wash the skin and eyes.

Usual dose:

Your doctor will tell you what dose to take and how to take it. Your doctor may adjust your dose until they find what works best for you. Never change your dose on your own.

Overdose:

If you think you have taken too much Advagraf, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

Missed dose:

If you miss a dose of Advagraf you may take it up to 14 hours from the scheduled time of your dose. For example, if you miss an 8:00 a.m. dose, you may take the missed dose by 10:00 p.m. If it has been more than 14 hours since the missed dose, do not take the missed dose. Wait until the usual scheduled time the following morning and take your next regular daily dose. Never take a double dose to make up for a missed dose.

What are possible side effects from using Advagraf?

These are not all the possible side effects you may feel when taking Advagraf. If you experience any side effects not listed here, contact your healthcare professional.

Common side effects may include:

- Anxiety
- Constipation
- Diarrhea
- Edema (swelling) of the legs and arms
- Headache
- Insomnia
- Tremor (shaking), especially of the hands

Advagraf can cause abnormal blood test results. Your doctor may perform blood tests and will interpret the results.

Like other medicines, Advagraf may cause side effects in some people. If you think that you are having side effects, talk to your doctor right away. **DO NOT stop taking Advagraf on your own.**

It is important to regularly tell your doctor how you are feeling and if you have developed any new symptoms while taking Advagraf.

Serious side effects and what to do about them

Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Anemia (decreased red blood cells): dizziness, fainting, fatigue, feeling unwell, lack of energy, pale skin, pale stool, rapid heartbeat, shortness of breath, weakness		✓	
Diabetes (high blood sugar): blurred vision, confusion, drowsiness, frequent urination, fruity smell on your breath, increased thirst and hunger, loss of appetite, nausea, stomach pain or vomiting		✓	
Hypertension (high blood pressure): usually without symptoms but can appear as altered vision, dizziness, fainting, headache, head feeling "light", tinnitus (buzzing or hissing in the ears), vertigo		✓	
Infections of urinary tract: frequent urination, pain or burning sensation when urinating, pain or pressure in lower back or abdomen, urine not looking or smelling normal		✓	
Leukopenia (decreased white blood cells): aches, fatigue, fever, infections, mouth ulcers, pains and flu-like symptoms, sweating		✓	
Liver problem: back pain, yellowing of the skin or eyes		✓	
Kidney problem: back and abdominal pain, change in the colour of urine (pale or dark), less urine produced, pain or discomfort when urinating, swelling of the legs and ankles		✓	
COMMON			
Infections of upper respiratory tract (sinus, nose, throat): common cold symptoms, cough, facial pain or pressure, fever, headache, nasal congestion, runny or stuffy nose, sneezing, sore throat		✓	

Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Infections: chills, fatigue, feeling unwell, fever, sore throat		✓	
Electrolyte disturbance (high/low blood levels of calcium, magnesium and/or phosphate): dehydration, diarrhea, eating disorders, vomiting		✓	
UNCOMMON			
Thrombotic microangiopathy: fever and bruising under the skin that may appear as red dots, with or without unexplained tiredness, confusion, yellowing of the skin or eyes, reduced urine output. When tacrolimus is taken together with sirolimus or everolimus, the risk of developing these symptoms may increase		✓	
RARE / UNKNOWN			
Posterior encephalopathy syndrome (a nervous system disorder): change in mental state, coma, confusion, numbness and tingling, headache, seizures, vision changes		✓	
Heart problems: abnormal heart rhythms, chest pain, dizziness, fainting, low or no pulse, nausea, pain irradiating in the arm, neck or back, palpitations, short breath, sweating			✓
Gastrointestinal perforation (a hole in your stomach or bowels): chills or fever, nausea, severe abdominal pain, vomiting			✓
Respiratory distress: chest pain, difficulty to breathe, short breath			✓
Sepsis: confusion, fever, low body temperature, rapid breathing, rapid heart rate, swelling			✓
Cancer: new or abnormal mole on the skin, patch on the skin that doesn't heal, or is itchy, bleeds or oozes, size or shape of an existing mole, skin ulcers (broken skin with an open wound), appearance of lumps in your breast or other areas of the body, a nagging cough or hoarseness, persistent and severe headaches, swollen lymph nodes, a change in your bladder or bowel habits		✓	
Progressive multifocal leukoencephalopathy (PML) (rare brain infection): changes in thinking, clumsiness of limbs, confusion, disturbance of vision, progressive weakness on one side of the body, memory and orientation, personality changes		✓	

Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Pure red cell aplasia (PRCA) (bone marrow stops producing red cells): dizziness, fainting, fatigue, feeling unwell, pale skin, pale stools, rapid heartbeat, shortness of breath, weakness		✓	
Febrile neutropenia (decrease in white blood cells): fever		✓	
Optic neuropathy (problem with the nerves in your eye): change or loss of vision		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature (15°C – 30°C).

Keep out of reach and sight of children.

If you want more information about Advagraf®:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <http://www.astellas.ca/>, or by calling 1-888-338-1824.

This leaflet was prepared by Astellas Pharma Canada, Inc.

Last Revised SEP 23, 2024

Prograf® and Advagraf® are registered trademarks of Astellas Pharma Inc. All other trademarks or registered trademarks are the property of their respective owners.